Équipe
Frédéric Chibon
ONCOSARC :
Oncogenèse des sarcomes
Les spécificités
de notre axe de recherches
Sarcome
Différenciation
Diagnostic
Génome
Oncogenèse
Pronostic
Chromosome
Metastase
Cellule tumorale hybride
Mitose
Traitement
Hétérogénéité
DES PROJETS
DE RECHERCHE
Oncogenèse des sarcomes
Frédéric Chibon
LES FOCUS
DE L’ÉQUIPE
Découvrir
Comprendre
Participer
En live
;
Nous recrutons!
Le groupe "Oncogenèse des sarcomes" de l'ONCOPOLE de Toulouse cherche à se renforcer, pour développer de nouveaux axes. Recherchons CR/DR INSERM.
Faites passer l'info, contactez moi!
Détail sur le site Rh de l'INSERM:https://rh.inserm.fr/Pages/default.aspx
PRODUCTIONS SCIENTIFIQUES
PUBLICATIONS 2025
7813506
CF9MRXB4
2025
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
PUBLICATIONS 2024
7813506
CF9MRXB4
2024
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Z6FCLZ75%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Saucier%20et%20al.%22%2C%22parsedDate%22%3A%222024-10-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSaucier%2C%20Emilie%2C%20Ga%26%23xEB%3Blle%20Bougeard%2C%20Anne%20Gomez-Mascard%2C%20Catherine%20Schramm%2C%20Rachid%20Abbas%2C%20Pablo%20Berlanga%2C%20Claire%20Briandet%2C%20et%20al.%20%26%23x201C%3BLi-Fraumeni-Associated%20Osteosarcomas%3A%20The%20French%20Experience.%26%23x201D%3B%20%26lt%3Bi%26gt%3BPediatric%20Blood%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20October%2010%2C%202024%2C%20e31362.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31362%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31362%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Li-Fraumeni-associated%20osteosarcomas%3A%20The%20French%20experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Saucier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Bougeard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Schramm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Berlanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Briandet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Castex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nad%5Cu00e8ge%22%2C%22lastName%22%3A%22Corradini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Coze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Guerrini-Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Guinebreti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Khneisser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Lervat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Mansuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Marec-Berard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Marie-Cardine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Saumet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Dominique%22%2C%22lastName%22%3A%22Tabone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Frebourg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Brugieres%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Describe%20clinical%20characteristics%20and%20outcome%20of%20Li-Fraumeni%20syndrome%20%28LFS%29-associated%20osteosarcomas.%5CnMETHODS%3A%20TP53%20germline%20pathogenic%5C%2Flikely%20pathogenic%20variant%20carriers%20diagnosed%20with%20osteosarcoma%20in%20France%20between%201980%20and%202019%20were%20identified%20via%20the%20French%20Li-Fraumeni%20database%20at%20Rouen%20University%20Hospital.%20Sixty-five%20osteosarcomas%20in%2052%20patients%20with%20available%20clinical%20and%20histological%20data%20were%20included.%20The%20main%20clinical%20characteristics%20were%20compared%20with%20data%20from%20National%20Cancer%20Institute%26%23039%3Bs%20SEER%20%28Surveillance%2C%20Epidemiology%2C%20and%20End%20Results%29%20for%20patients%20of%20the%20same%20age%20group.%5CnRESULTS%3A%20Median%20age%20at%20first%20osteosarcoma%20diagnosis%20was%2013.7%5Cu00a0years%20%28range%3A%205.9-36.7%29.%20Compared%20to%20unselected%20osteosarcomas%2C%20LFS-associated%20osteosarcomas%20occurred%20more%20frequently%20in%20patients%20less%20than%2010%5Cu00a0years%20of%20age%20%2823%25%20vs.%209%25%29%2C%20and%20when%20compared%20with%20osteosarcomas%20in%20patients%20less%20than%2025%5Cu00a0years%20were%20characterized%20by%20an%20excess%20of%20axial%20%2816%25%20vs.%2010%25%29%20and%20jaw%20sites%20%2815%25%20vs.%203%25%29%20and%20histology%20with%20predominant%20chondroblastic%20component%20and%20periosteal%20subtypes%20%2817%25%20vs.%201%25%29.%20Metastases%20incidence%20%2825%25%29%20was%20as%20expected%20in%20osteosarcomas.%20After%20the%20first%20osteosarcoma%20treatment%2C%20the%20rate%20of%20good%20histologic%20response%20%2862%25%29%20and%20the%205-year%20progression-free%20survival%20%2855%25%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%2042.6-71.1%29%20were%20as%20expected%20in%20unselected%20series%20of%20osteosarcomas%2C%20whereas%20the%205-year%20event-free%20survival%20was%2036.5%25%20%5B95%25%20CI%3A%2025.3-52.7%5D%20due%20to%20the%20high%20incidence%20of%20second%20malignancies%20reaching%20a%2010-year%20cumulative%20risk%20of%2043.4%25%20%5B95%25%20CI%3A%2028.5-57.5%5D.%5CnCONCLUSION%3A%20In%20osteosarcoma%2C%20young%20age%20at%20diagnosis%2C%20axial%20and%20jaw%20sites%2C%20histology%20with%20periosteal%20or%20chondroblastic%20subtype%2C%20and%20synchronous%20multifocal%20tumors%20should%20prompt%20suspicion%20of%20a%20germline%20TP53%20mutation.%20Standard%20treatments%20are%20effective%2C%20but%20multiple%20malignancies%20impair%20prognosis.%20Early%20recognition%20of%20these%20patients%20is%20crucial%20for%20tailored%20therapy%20and%20follow-up.%22%2C%22date%22%3A%222024-10-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fpbc.31362%22%2C%22ISSN%22%3A%221545-5017%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222024-10-28T13%3A16%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22HAFEJFU8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bastard%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBastard%2C%20Paul%2C%20Nathalie%20Cozic%2C%20R%26%23xE9%3Bgis%20Brion%2C%20Nathalie%20Gaspar%2C%20Sophie%20Piperno-Neumann%2C%20Camille%20Cordero%2C%20Estelle%20Lecul%26%23xE9%3Be-Th%26%23xE9%3Bbaud%2C%20et%20al.%20%26%23x201C%3BPrognostic%20Value%20of%20Hemogram%20Parameters%20in%20Osteosarcoma%3A%20The%20French%20OS2006%20Experience.%26%23x201D%3B%20%26lt%3Bi%26gt%3BPediatric%20Blood%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20April%2028%2C%202024%2C%20e31029.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31029%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31029%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prognostic%20value%20of%20hemogram%20parameters%20in%20osteosarcoma%3A%20The%20French%20OS2006%20experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Bastard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Cozic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9gis%22%2C%22lastName%22%3A%22Brion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Lecul%5Cu00e9e-Th%5Cu00e9baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22R%5Cu00e9dini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonin%22%2C%22lastName%22%3A%22Marchais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raina%22%2C%22lastName%22%3A%22Ikonomova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Cleirec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Laurence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Rigaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Verrecchia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Brugi%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Minard-Colin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Previous%20studies%20have%20shown%20that%20neutrophil-to-lymphocyte%20%28NLR%29%20ratio%20at%20diagnosis%20and%20early%20lymphocytes%20recovery%20on%20doxorubicin-based%20chemotherapy%2C%20may%20impact%20the%20outcome%20in%20patients%20with%20osteosarcoma%20%28OST%29.%20This%20study%20aimed%20to%20evaluate%20the%20prognostic%20value%20of%20hemogram%20parameters%20in%20patients%20with%20OST%20treated%20with%20high-dose%20methotrexate%20and%20etoposide%5C%2Fifosfamide%20%28M-EI%29%20chemotherapy.%5CnMATERIALS%20AND%20METHODS%3A%20We%20retrospectively%20analyzed%20the%20prognostic%20value%20of%20various%20hemogram%20parameters%20at%20diagnosis%20and%20during%20therapy%20in%20a%20large%20consecutive%20cohort%20of%20patients%20with%20OST%20included%20in%20the%20French%20OS2006%20trial%20and%20treated%20with%20M-EI%20chemotherapy.%5CnRESULTS%3A%20A%20total%20of%20164%20patients%20were%20analyzed.%20The%20median%20age%20was%2014.7%5Cu00a0years%20%28interquartile%20range%20%5BIQR%5D%3A%2011.7-17%29.%20Median%20follow-up%20was%205.6%5Cu00a0years%20%28IQR%3A%203.3-7.7%5Cu00a0years%29.%20Three-year%20event-free%20survival%20%28EFS%29%20and%20overall%20survival%20%28OS%29%20were%2071.5%25%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%2064%25-78%25%29%20and%2086.4%25%20%2895%25%20CI%3A%2080%25-91%25%29%2C%20respectively.%20In%20univariate%20analysis%2C%20blood%20count%20parameters%20at%20diagnosis%20and%20early%20lymphocyte%20recovery%20at%20Day%2014%20were%20not%20found%20prognostic%20of%20survival%20outcomes.%20By%20contrast%2C%20an%20increase%20of%20NLR%20ratio%20at%20Day%201%20of%20the%20first%20EI%20chemotherapy%20%28NLR-W4%29%20was%20associated%20with%20reduced%20OS%20in%20univariate%20%28p%5Cu00a0%3D%5Cu00a0.0044%29%20and%20multivariate%20analysis%20%28hazards%20ratio%20%5BHR%5D%5Cu00a0%3D%5Cu00a01.3%2C%2095%25%20CI%3A%201.1-1.5%3B%20p%5Cu00a0%3D%5Cu00a0.002%29%2C%20although%20not%20with%20EFS.%20After%20adjustment%20on%20histological%20response%20and%20metastatic%20status%2C%20an%20increase%20of%20the%20ratio%20NLR-W4%20of%201%20was%20associated%20with%20an%20increased%20risk%20of%20death%20of%2030%25.%5CnCONCLUSIONS%3A%20We%20identified%20NLR-W4%20as%20a%20potential%20early%20biomarker%20for%20survival%20in%20patients%20with%20OST%20treated%20with%20M-EI%20chemotherapy.%20Further%20studies%20are%20required%20to%20confirm%20the%20prognostic%20value%20of%20NLR%20and%20better%20identify%20immune%20mechanisms%20involved%20in%20disease%20surveillance.%22%2C%22date%22%3A%222024-04-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fpbc.31029%22%2C%22ISSN%22%3A%221545-5017%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222024-05-13T16%3A50%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22NK4DV4HY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Del%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDel%2C%20Mathilde%2C%20Claire%20Illac%2C%20Mathilde%20Morisseau%2C%20Martina%20Aida%20Angeles%2C%20Anne%20Ducassou%2C%20Sarah%20Betrian%2C%20Guillaume%20Bataillon%2C%20et%20al.%20%26%23x201C%3BIntraepithelial%20Tumor-Infiltrating%20Lymphocytes%20Shape%20Loco-Regional%20PET%5C%2FCT%20Spread%20of%20Locally%20Advanced%20Cervical%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2034%2C%20no.%204%20%28April%201%2C%202024%29%3A%20490%26%23x2013%3B96.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2023-004677%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2023-004677%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intraepithelial%20tumor-infiltrating%20lymphocytes%20shape%20loco-regional%20PET%5C%2FCT%20spread%20of%20locally%20advanced%20cervical%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Del%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Illac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Morisseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Betrian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Bataillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Chantalat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Gabiache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Data%20suggest%20an%20association%20between%20positron%20emission%20tomography%5C%2FCT%20%28PET%5C%2FCT%29%20metabolic%20metrics%20and%20tumor%20microenvironment%20in%20several%20malignancies%2C%20and%20a%20potential%20role%20of%20PET%5C%2FCT%20to%20monitor%20response%20to%20immunotherapy.%5CnOBJECTIVE%3A%20To%20evaluate%20the%20correlation%20between%20tumor%20loco-regional%20extension%20and%20tumor-infiltrating%20lymphocyte%20infiltration%20in%20locally%20advanced%20cervical%20cancer%20prior%20to%20concurrent%20chemo-radiotherapy.The%20secondary%20objective%20was%20to%20assess%20the%20association%20between%20tumor-infiltrating%20lymphocytes%20and%20PET%5C%2FCT%20metabolic%20metrics.%5CnMETHODS%3A%20Patients%20with%20locally%20advanced%20cervical%20cancer%20and%20negative%20para-aortic%20extensions%20on%20PET%5C%2FCT%20were%20included.%20Two%20senior%20nuclear%20medicine%20physicians%20specializing%20in%20gynecologic%20oncology%20reviewed%20all%20PET%5C%2FCT%20exams%2C%20and%20extracted%20tumor%20maximum%20standardized%20uptake%20value%2C%20metabolic%20tumor%20volume%2C%20and%20total%20lesion%20glycolysis%2C%20as%20well%20as%20pelvic%20lymph%20node%20involvement.%20One%20senior%20gynecologic%20oncology%20pathologist%20assessed%20intraepithelial%20tumor-infiltrating%20lymphocytes%20and%20stromal%20tumor-infiltrating%20lymphocytes.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20categorized%20following%20previous%20studies%20as%20%26lt%3B1%25%20and%20%26gt%3B1%25.%20The%20cut-off%20for%20stromal%20tumor-infiltrating%20lymphocytes%20was%20chosen%20empirically%3A%20intermediate%20%26lt%3B60%25%20and%20high%20%26gt%3B60%25.%5CnRESULTS%3A%2086%20patients%20were%20included.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20not%20significantly%20associated%20with%20tumor%20metabolic%20metrics.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20not%20significantly%20associated%20with%20maximum%20standard%20uptake%20value%20%28p%3D0.16%29%2C%20or%20metabolic%20tumor%20volume%20%28p%3D0.19%29.%20Tumors%20with%20%26lt%3B1%25%20intraepithelial%20tumor-infiltrating%20lymphocytes%20score%20were%20associated%20with%20a%20higher%20MRI%20tumor%20size%20%28%5Cu2265%20median%29%20%2863.3%25%20vs%2039.3%25%2C%20p%3D0.04%29.%20Patients%20with%20pelvic%20lymph%20node%20uptake%20were%20significantly%20more%20frequent%20in%20patients%20with%20high%20stromal%20tumor-infiltrating%20lymphocytes%20score%20%28%5Cu226560%25%29%20%2861.5%25%20vs%2031.7%25%2C%20p%3D0.009%29.%5CnCONCLUSIONS%3A%20Poor%20or%20absent%20intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20associated%20with%20more%20advanced%20disease%20at%20diagnosis%20and%20larger%20tumor%20size.%20Tumor-infiltrating%20lymphocytes%20were%20not%20associated%20with%20tumor%20metabolic%20activity.%20Intraepithelial%20and%20stroma%20tumor-infiltrating%20lymphocytes%20are%20not%20redundant%20and%20should%20be%20assessed%20separately.%20Further%20work%20is%20needed%20to%20evaluate%20the%20association%20between%20tumor%20metabolic%20profile%20and%20immune%20populations%2C%20including%20different%20T-cell%20subtypes%20for%20patient%20selection%20for%20immunotherapy%20strategies.%22%2C%22date%22%3A%222024-04-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2023-004677%22%2C%22ISSN%22%3A%221525-1438%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222024-06-07T08%3A05%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22P3CRM7KI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ricotta%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRicotta%2C%20Giulio%2C%20Elodie%20Gauroy%2C%20Anne-Sophie%20Navarro%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BHow%20to%20Reduce%20Anterior%20Resection%20Syndrome%20and%20Post-Operative%20Complication%20after%20Rectosigmoid%20Resection.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2028%2C%202024%2C%20ijgc%26%23x2013%3B2024%26%23x2013%3B005306.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2024-005306%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2024-005306%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20to%20reduce%20anterior%20resection%20syndrome%20and%20post-operative%20complication%20after%20rectosigmoid%20resection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%22%2C%22lastName%22%3A%22Ricotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gauroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-03-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2024-005306%22%2C%22ISSN%22%3A%221525-1438%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222024-04-02T14%3A14%3A34Z%22%7D%7D%5D%7D
Saucier, Emilie, Gaëlle Bougeard, Anne Gomez-Mascard, Catherine Schramm, Rachid Abbas, Pablo Berlanga, Claire Briandet, et al. “Li-Fraumeni-Associated Osteosarcomas: The French Experience.” Pediatric Blood & Cancer, October 10, 2024, e31362. https://doi.org/10.1002/pbc.31362.
Bastard, Paul, Nathalie Cozic, Régis Brion, Nathalie Gaspar, Sophie Piperno-Neumann, Camille Cordero, Estelle Leculée-Thébaud, et al. “Prognostic Value of Hemogram Parameters in Osteosarcoma: The French OS2006 Experience.” Pediatric Blood & Cancer, April 28, 2024, e31029. https://doi.org/10.1002/pbc.31029.
Del, Mathilde, Claire Illac, Mathilde Morisseau, Martina Aida Angeles, Anne Ducassou, Sarah Betrian, Guillaume Bataillon, et al. “Intraepithelial Tumor-Infiltrating Lymphocytes Shape Loco-Regional PET/CT Spread of Locally Advanced Cervical Cancer.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 34, no. 4 (April 1, 2024): 490–96. https://doi.org/10.1136/ijgc-2023-004677.
Ricotta, Giulio, Elodie Gauroy, Anne-Sophie Navarro, Alejandra Martinez, and Gwenael Ferron. “How to Reduce Anterior Resection Syndrome and Post-Operative Complication after Rectosigmoid Resection.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, March 28, 2024, ijgc–2024–005306. https://doi.org/10.1136/ijgc-2024-005306.
PUBLICATIONS 2023
7813506
CF9MRXB4
2023
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22555A2C8N%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Frezza%20et%20al.%22%2C%22parsedDate%22%3A%222023-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFrezza%2C%20Anna%20Maria%2C%20Silvia%20Stacchiotti%2C%20Frederic%20Chibon%2C%20Jean-Michelle%20Coindre%2C%20Antoine%20Italiano%2C%20Cleofe%20Romagnosa%2C%20Silvia%20Bagu%26%23xE9%3B%2C%20et%20al.%20%26%23x201C%3BCINSARC%20in%20High-Risk%20Soft%20Tissue%20Sarcoma%20Patients%20Treated%20with%20Neoadjuvant%20Chemotherapy%3A%20Results%20from%20the%20ISG-STS%201001%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%202%20%28January%202023%29%3A%201350%26%23x2013%3B57.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.5015%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.5015%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CINSARC%20in%20high-risk%20soft%20tissue%20sarcoma%20patients%20treated%20with%20neoadjuvant%20chemotherapy%3A%20Results%20from%20the%20ISG-STS%201001%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Maria%22%2C%22lastName%22%3A%22Frezza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Stacchiotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michelle%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleofe%22%2C%22lastName%22%3A%22Romagnosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Bagu%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%20Paolo%22%2C%22lastName%22%3A%22Dei%20Tos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luca%22%2C%22lastName%22%3A%22Braglia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Palmerini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vittorio%22%2C%22lastName%22%3A%22Quagliuolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%20Martin%22%2C%22lastName%22%3A%22Broto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Lopez%20Pousa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Grignani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22Brunello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20Diaz%22%2C%22lastName%22%3A%22Beveridge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iwona%22%2C%22lastName%22%3A%22Lugowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberta%22%2C%22lastName%22%3A%22Maestro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franco%20Domenico%22%2C%22lastName%22%3A%22Merlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%20Giovanni%22%2C%22lastName%22%3A%22Casali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Gronchi%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20Complexity%20INdex%20in%20SARComas%20%28CINSARC%29%20is%20a%20transcriptional%20signature%20derived%20from%20the%20expression%20of%2067%20genes%20involved%20in%20mitosis%20control%20and%20chromosome%20integrity.%20This%20study%20aims%20to%20assess%20CINSARC%20value%20of%20in%20an%20independent%20series%20of%20high-risk%20patients%20with%20localized%20soft%20tissue%20sarcoma%20%28STS%29%20treated%20with%20preoperative%20chemotherapy%20within%20a%20prospective%2C%20randomized%2C%20phase%20III%20study%20%28ISG-STS%201001%29.%5CnPATIENTS%20AND%20METHODS%3A%20Patients%20with%20available%20pre-treatment%20samples%2C%20treated%20with%203%20cycles%20of%20either%20standard%20%28ST%29%20preoperative%20or%20histotype-tailored%20%28HT%29%20chemotherapy%2C%20were%20scored%20according%20to%20CINSARC%20%28low-risk%2C%20C1%3B%20high-risk%2C%20C2%29.%20The%2010-year%20overall%20survival%20probability%20%28pr-OS%29%20according%20to%20SARCULATOR%20was%20calculated%2C%20and%20patients%20were%20classified%20accordingly%20%28low-risk%2C%20Sarc-LR%2C%2010-year%20pr-OS%26gt%3B60%25%3B%20high-risk%2C%20Sarc-HR%2C%2010-year%20pr-OS%26lt%3B60%25%29.%20Survival%20functions%20were%20estimated%20using%20the%20Kaplan-Meier%20method%20and%20compared%20using%20log-rank%20test.%5CnRESULTS%3A%20Eighty-six%20patients%20were%20included%2C%2030%20C1%20and%2056%20C2%2C%2049%20Sarc-LR%20and%2037%20Sarc-HR.%20A%20low%20level%20of%20agreement%20between%20CINSARC%20and%20SARCULATOR%20was%20observed%20%28Cohen%26%23039%3Bs%20Kappa%5Cu00a0%3D%5Cu00a00.174%29.%20The%205-year%20relapse-free%20survival%20in%20C1%20and%20C2%20were%200.57%20and%200.55%20%28p%5Cu00a0%3D%5Cu20090.481%29%3B%205-year%20metastases-free%20survival%200.63%20and%200.64%20%28p%5Cu00a0%3D%5Cu20090.740%29%3B%205-year%20OS%200.80%20and%200.72%20%28p%5Cu00a0%3D%5Cu20090.460%29.%20The%205-year%20OS%20in%20C1%20treated%20with%20ST%20and%20HT%20chemotherapy%20was%200.84%20and%200.76%20%28p%5Cu00a0%3D%5Cu20090.251%29%20respectively%3B%20in%20C2%20treated%20it%20was%200.72%20and%200.70%20%28p%5Cu00a0%3D%5Cu20090.349%29.%20The%205-year%20OS%20in%20Sarc-LR%20treated%20with%20S%20and%20HT%20chemotherapy%20was%200.80%20and%200.82%20%28p%5Cu00a0%3D%5Cu20090.502%29%20respectively%3B%20in%20Sarc-HR%20it%20was%200.70%20and%200.61%20%28p%5Cu00a0%3D%5Cu20090.233%29.%5CnCONCLUSIONS%3A%20Our%20results%2C%20although%20constrained%20by%20the%20small%20size%20of%20the%20series%2C%20suggest%20that%20CINSARC%20has%20weak%20prognostic%20power%20in%20high-risk%2C%20localized%20STS%20treated%20with%20neoadjuvant%20chemotherapy.%22%2C%22date%22%3A%222023-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcam4.5015%22%2C%22ISSN%22%3A%222045-7634%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222023-02-07T13%3A36%3A07Z%22%7D%7D%5D%7D
Frezza, Anna Maria, Silvia Stacchiotti, Frederic Chibon, Jean-Michelle Coindre, Antoine Italiano, Cleofe Romagnosa, Silvia Bagué, et al. “CINSARC in High-Risk Soft Tissue Sarcoma Patients Treated with Neoadjuvant Chemotherapy: Results from the ISG-STS 1001 Study.” Cancer Medicine 12, no. 2 (January 2023): 1350–57. https://doi.org/10.1002/cam4.5015.
PUBLICATIONS 2022
7813506
CF9MRXB4
2022
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22A5QIFHFI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brunac%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrunac%2C%20Anne-C%26%23xE9%3Bcile%2C%20Joanna%20Fourquet%2C%20Ga%26%23xEB%3Blle%20Perot%2C%20Marion%20Jaffrelot%2C%20Julie%20Meilleroux%2C%20Marie%20Danjoux%2C%20Thomas%20Filleron%2C%20et%20al.%20%26%23x201C%3BCINSARC%20Signature%20Outperforms%20Gold-Standard%20TNM%20Staging%20and%20Consensus%20Molecular%20Subtypes%20for%20Clinical%20Outcome%20in%20Stage%20II-III%20Colorectal%20Carcinoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BModern%20Pathology%3A%20An%20Official%20Journal%20of%20the%20United%20States%20and%20Canadian%20Academy%20of%20Pathology%2C%20Inc%26lt%3B%5C%2Fi%26gt%3B%2C%20October%206%2C%202022.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-022-01166-9%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-022-01166-9%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CINSARC%20signature%20outperforms%20gold-standard%20TNM%20staging%20and%20consensus%20molecular%20subtypes%20for%20clinical%20outcome%20in%20stage%20II-III%20colorectal%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-C%5Cu00e9cile%22%2C%22lastName%22%3A%22Brunac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%22%2C%22lastName%22%3A%22Fourquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Perot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Jaffrelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Meilleroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Danjoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Nicola%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samira%22%2C%22lastName%22%3A%22Icher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadim%22%2C%22lastName%22%3A%22Far%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22The%20outcome%20of%20stage%20II-III%20colorectal%20cancer%20%28CRC%29%20is%20highly%20variable%20and%20therapeutic%20choice%20is%20currently%20based%20on%20TNM%20staging%20with%20a%20few%20additional%20biomarkers.%20However%2C%20studies%20show%20that%20some%20stage%20III%20patients%20have%20a%20better%20prognosis%20than%20some%20stage%20II%20patients.%20A%20promising%20consensus%20molecular%20%28CMS%29%20classification%20with%20prognostic%20relevance%20has%20been%20developed%2C%20but%20it%20is%20not%20used%20in%20daily%20practice.%20Our%20team%20developed%20CINSARC%2C%20a%2067-gene%20expression%20prognostic%20signature%2C%20whose%20prognostic%20value%20has%20been%20demonstrated%20in%20many%20cancer%20types.%20It%20is%20applicable%20to%20formalin-fixed%2C%20paraffin-embedded%20%28FFPE%29%20blocks%20using%20NanoString%5Cu00ae%20technology.%20We%20investigated%20whether%20it%20could%20predict%20outcome%20in%20stage%20II-III%20CRC.%20We%20established%20the%20CINSARC%20classification%20on%20the%20TCGA%20retrospective%20cohort%20comprising%20297%20stage%20II-III%20CRC%20patients%20using%20RNA%20sequencing%20and%20on%20a%20second%20independent%20cohort%20comprising%20169%20cases%20using%20NanoString%5Cu00ae%20technology.%20We%20compared%20its%20recurrence-free%20and%20overall%20survival%20prognostic%20value%20with%20TNM%20staging%20and%20CMS%20classification.%20In%20the%20TCGA%20cohort%2C%20we%20showed%20that%20CINSARC%20significantly%20splits%20the%20population%20of%20stage%20II-III%20CRC%20into%20two%20groups%20with%20different%20progression-free%20interval%20%28P%5Cu2009%3D%5Cu20091.68%5Cu2009%5Cu00d7%5Cu200910-2%3B%20HR%5Cu2009%3D%5Cu20091.87%20%5B1.11-3.16%5D%29%20and%20overall%20survival%20%28P%5Cu2009%3D%5Cu20093.73%5Cu2009%5Cu00d7%5Cu200910-3%3B%20HR%5Cu2009%3D%5Cu20092.45%20%5B1.31-4.59%5D%29%20and%20is%20a%20strong%20prognostic%20factor%20in%20multivariate%20analysis%2C%20outperforming%20TNM%20staging%20and%20CMS%20classification.%20We%20validated%20these%20results%20in%20the%20second%20cohort%20by%20applying%20CINSARC%20on%20FFPE%20samples%20with%20Nanostring%5Cu00ae%20technology.%20CINSARC%20is%20a%20ready-to-use%20tool%20with%20a%20robust%20independent%20prognostic%20value%20in%20stage%20II-III%20CRC.%22%2C%22date%22%3A%222022-10-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41379-022-01166-9%22%2C%22ISSN%22%3A%221530-0285%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-10-25T19%3A12%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22MXLCE4LK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20Alicia%20Hern%26%23xE1%3Bndez%2C%20Asunci%26%23xF3%3Bn%20P%26%23xE9%3Brez-Benavente%2C%20Bastien%20Cabarrou%2C%20Emanuela%20Spagnolo%2C%20Agnieszka%20Rychlik%2C%20Amel%20Daboussi%2C%20et%20al.%20%26%23x201C%3BThe%20Effect%20of%20Major%20Postoperative%20Complications%20on%20Recurrence%20and%20Long-Term%20Survival%20after%20Cytoreductive%20Surgery%20for%20Ovarian%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%20166%2C%20no.%201%20%28July%202022%29%3A%208%26%23x2013%3B17.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.05.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.05.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20major%20postoperative%20complications%20on%20recurrence%20and%20long-term%20survival%20after%20cytoreductive%20surgery%20for%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asunci%5Cu00f3n%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Benavente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Spagnolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnieszka%22%2C%22lastName%22%3A%22Rychlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amel%22%2C%22lastName%22%3A%22Daboussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22B%5Cu00e9trian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil-Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20assess%20the%20impact%20on%20survival%20of%20major%20postoperative%20complications%20and%20to%20identify%20the%20factors%20associated%20with%20these%20complications%20in%20patients%20with%20advanced%20ovarian%20cancer%20after%20cytoreductive%20surgery.%5CnMETHODS%3A%20We%20designed%20a%20retrospective%20multicenter%20study%20collecting%20data%20from%20patients%20with%20IIIC-IV%20FIGO%20Stage%20ovarian%20cancer%20who%20had%20undergone%20either%20primary%20debulking%20surgery%20%28PDS%29%2C%20early%20interval%20debulking%20surgery%20%28IDS%29%20after%203-4%20cycles%20of%20neoadjuvant%20chemotherapy%2C%20or%20delayed%20debulking%20surgery%20%28DDS%29%20after%206%20cycles%2C%20with%20minimal%20or%20no%20residual%20disease%2C%20from%20January%202008%20to%20December%202015.%20Univariable%20and%20multivariable%20analyses%20were%20conducted%20to%20identify%20factors%20associated%20with%20major%20surgical%20complications%20%28%5Cu2265Grade%203%29.%20We%20assessed%20disease-free%20survival%20%28DFS%29%20and%20overall%20survival%20%28OS%29%20rates%20according%20to%20the%20occurrence%20of%20major%20postoperative%20complications.%5CnRESULTS%3A%20549%20women%20were%20included.%20The%20overall%20rate%20of%20major%20surgical%20complications%20was%2022.4%25.%20Patients%20who%20underwent%20PDS%20had%20a%20higher%20rate%20of%20major%20complications%20%2828.6%25%29%20than%20patients%20who%20underwent%20either%20early%20IDS%20%2823.2%25%29%20or%20DDS%20%2814.0%25%29.%20Multivariable%20analysis%20revealed%20that%20extensive%20peritonectomy%20and%20surgical%20timing%20were%20associated%20with%20the%20occurrence%20of%20major%20complications.%20Median%20DFS%20and%20OS%20were%2016.9%20months%20%2895%25CI%20%3D%20%5B13.7-18.4%5D%29%20and%2048.0%20months%20%2895%25CI%20%3D%20%5B37.2-73.1%5D%29%20for%20the%20group%20of%20patients%20with%20major%20complications%2C%20and%2020.1%20months%20%2895%25CI%20%3D%20%5B18.6-22.4%5D%29%20and%2056.7%20months%20%2895%25CI%20%3D%20%5B51.2-70.4%5D%29%20for%20the%20group%20without%20major%20complications.%20Multivariable%20analysis%20revealed%20that%20major%20surgical%20complications%20were%20significantly%20associated%20with%20DFS%2C%20but%20not%20with%20OS.%5CnCONCLUSIONS%3A%20Patients%20who%20experienced%20major%20surgical%20complications%20had%20reduced%20DFS%2C%20compared%20with%20patients%20without%20major%20morbidity.%20Extensive%20peritonectomy%20and%20surgical%20timing%20were%20predictive%20factors%20of%20postoperative%20morbidity.%22%2C%22date%22%3A%222022-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ygyno.2022.05.002%22%2C%22ISSN%22%3A%221095-6859%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-06-28T07%3A46%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22E6EECT24%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fayet%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFayet%2C%20Yohan%2C%20Christine%20Chevreau%2C%20Gauthier%20Decanter%2C%20C%26%23xE9%3Bcile%20Dalban%2C%20Pierre%20Meeus%2C%20S%26%23xE9%3Bbastien%20Carr%26%23xE8%3Bre%2C%20Leila%20Haddag-Miliani%2C%20et%20al.%20%26%23x201C%3BNo%20Geographical%20Inequalities%20in%20Survival%20for%20Sarcoma%20Patients%20in%20France%3A%20A%20Reference%20Networks%26%23x2019%3B%20Outcome%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2014%2C%20no.%2011%20%28May%2025%2C%202022%29%3A%202620.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14112620%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14112620%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22No%20Geographical%20Inequalities%20in%20Survival%20for%20Sarcoma%20Patients%20in%20France%3A%20A%20Reference%20Networks%27%20Outcome%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohan%22%2C%22lastName%22%3A%22Fayet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gauthier%22%2C%22lastName%22%3A%22Decanter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Dalban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Meeus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Carr%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Haddag-Miliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Causeret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Orbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Kind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis-Rom%5Cu00e9e%22%2C%22lastName%22%3A%22Le%20Nail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Labrosse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Chaigneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Bertucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Ruzic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Le%20Brun%20Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fadila%22%2C%22lastName%22%3A%22Farsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Noal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Vozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Ducoulombier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Chabaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Ducimeti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Tlemsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Micka%5Cu00ebl%22%2C%22lastName%22%3A%22Ropars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Collard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Michelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gantzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Dubray-Longeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Soibinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Duffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Gouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22T%5Cu00e9treau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Ray-Coquard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%5D%2C%22abstractNote%22%3A%22The%20national%20reference%20network%20NETSARC%2B%20provides%20remote%20access%20to%20specialized%20diagnosis%20and%20the%20Multidisciplinary%20Tumour%20Board%20%28MTB%29%20to%20improve%20the%20management%20and%20survival%20of%20sarcoma%20patients%20in%20France.%20The%20IG%5Cu00e9AS%20research%20program%20aims%20to%20assess%20the%20potential%20of%20this%20innovative%20organization%20to%20address%20geographical%20inequalities%20in%20cancer%20management.%20Using%20the%20IG%5Cu00e9AS%20cohort%20built%20from%20the%20nationwide%20NETSARC%2B%20database%2C%20the%20individual%2C%20clinical%2C%20and%20geographical%20determinants%20of%20the%203-year%20overall%20survival%20of%20sarcoma%20patients%20in%20France%20were%20analyzed.%20The%20survival%20analysis%20was%20focused%20on%20patients%20diagnosed%20in%202013%20%28n%20%3D%202281%29%20to%20ensure%20sufficient%20hindsight%20to%20collect%20patient%20follow-up.%20Our%20study%20included%20patients%20with%20bone%20%2816.8%25%29%2C%20soft-tissue%20%2869%25%29%2C%20and%20visceral%20%2814.2%25%29%20sarcomas%2C%20with%20a%20median%20age%20of%2061.8%20years.%20The%20overall%20survival%20was%20not%20associated%20with%20geographical%20variables%20after%20adjustment%20for%20individual%20and%20clinical%20factors.%20The%20lower%20survival%20in%20precarious%20population%20districts%20%5BHR%201.23%2C%2095%25%20CI%201.02%20to%201.48%5D%20in%20comparison%20to%20wealthy%20metropolitan%20areas%20%28HR%20%3D%201%29%20found%20in%20univariable%20analysis%20was%20due%20to%20the%20worst%20clinical%20presentation%20at%20diagnosis%20of%20patients.%20The%20place%20of%20residence%20had%20no%20impact%20on%20sarcoma%20patients%26%23039%3B%20survival%2C%20in%20the%20context%20of%20the%20national%20organization%20driven%20by%20the%20reference%20network.%20Following%20previous%20findings%2C%20this%20suggests%20the%20ability%20of%20this%20organization%20to%20go%20through%20geographical%20barriers%20usually%20impeding%20the%20optimal%20management%20of%20cancer%20patients.%22%2C%22date%22%3A%222022-05-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14112620%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-06-13T08%3A38%3A47Z%22%7D%7D%2C%7B%22key%22%3A%225CUD6LFS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Krantschenko%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKrantschenko%2C%20Emma%2C%20Paul%20Khayat%2C%20Aurore%20Siegfried%2C%20Nathalie%20Van%20Acker%2C%20and%20Anne%20Gomez-Brouchet.%20%26%23x201C%3B%5BBone-forming%20lesions%20and%20rearrangements%20of%20FOS%20genes%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20De%20Pathologie%26lt%3B%5C%2Fi%26gt%3B%2042%2C%20no.%203%20%28April%202022%29%3A%20208%26%23x2013%3B13.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.01.013%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.01.013%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BBone-forming%20lesions%20and%20rearrangements%20of%20FOS%20genes%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Krantschenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Khayat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Van%20Acker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-04%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2022.01.013%22%2C%22ISSN%22%3A%220242-6498%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-06-13T10%3A39%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22B9WBALIX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daix%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-21%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDaix%2C%20Manon%2C%20Carlos%20Martinez%20Gomez%2C%20Martina%20Aida%20Angeles%2C%20St%26%23xE9%3Bphanie%20Tock%2C%20Laurence%20Gladieff%2C%20Erwan%20Gabiache%2C%20Eliane%20Mery%2C%20Alejandra%20Martinez%2C%20David%20Cibula%2C%20and%20Gw%26%23xE9%3Bna%26%23xEB%3Bl%20Ferron.%20%26%23x201C%3BExtended%20Pelvic%20Resection%20for%20Gynecological%20Malignancies%3A%20A%20Review%20of%20out-of-the-Box%20Surgery.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2021%2C%202022%2C%20S0090-8258%2822%2900174-3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.03.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.03.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extended%20pelvic%20resection%20for%20gynecological%20malignancies%3A%20A%20review%20of%20out-of-the-box%20surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez%20Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Tock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Gabiache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cibula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22The%20term%20%26%23039%3Bout-of-the-box%20surgery%26%23039%3B%20in%20gynecologic%20oncology%20was%20recently%20coined%20to%20describe%20the%20resection%20of%20tumor%20growing%20out%20of%20the%20endopelvic%20cavity.%20In%20the%20specific%20case%20of%20pelvic%20sidewall%20involvement%2C%20a%20laterally%20extended%20pelvic%20resection%20may%20be%20required.%20As%20previously%20defined%20by%20H%5Cu00f6ckel%2C%20this%20resection%20requires%20the%20en%20bloc%20removal%20of%20structures%20including%20the%20pelvic%20sidewall%20muscles%2C%20bones%2C%20nerves%2C%20and%5C%2For%20major%20vessels.%20This%20complex%20radical%20procedure%20leads%20to%20tumor-free%20margins%20in%20more%20than%2075%25%20of%20the%20patients%2C%20with%20reliable%20functional%20results.%20The%20rate%20of%20recurrence%20and%20overall%20survival%20are%20directly%20correlated%20with%20clear%20resection%20margins.%20Progress%20in%20imaging%2C%20surgical%20techniques%2C%20and%20perioperative%20care%20currently%20offer%20the%20opportunity%20to%20attempt%20surgical%20curative%20resection%20in%20selected%20patients%20for%20whom%20palliative%20therapy%20was%20the%20only%20alternative.%20However%2C%20the%20procedure%20is%20associated%20with%20a%20high%20rate%20of%20major%20postoperative%20complications%20affecting%20up%20to%2060%25%20of%20patients.%20Multidisciplinary%20expert%20centers%20are%20the%20most%20likely%20to%20achieve%20this%20complex%20surgery%20with%20favorable%20oncological%20outcomes.%20The%20aim%20of%20this%20review%20is%20to%20summarize%20the%20key%20issues%20of%20out-of-the-box%20surgery%20in%20gynecologic%20cancer.%22%2C%22date%22%3A%222022-03-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ygyno.2022.03.002%22%2C%22ISSN%22%3A%221095-6859%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22U3V2CBBY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marchais%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-25%22%2C%22numChildren%22%3A9%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMarchais%2C%20Antonin%2C%20Maria%20Eugenia%20Marques%20Da%20Costa%2C%20Bastien%20Job%2C%20Rachid%20Abbas%2C%20Damien%20Drubay%2C%20Sophie%20Piperno-Neumann%2C%20Olivia%20Fromigu%26%23xE9%3B%2C%20et%20al.%20%26%23x201C%3BImmune%20Infiltrate%20and%20Tumor%20Microenvironment%20Transcriptional%20Programs%20Stratify%20Pediatric%20Osteosarcoma%20into%20Prognostic%20Groups%20at%20Diagnosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2025%2C%202022%2C%20canres.CAN-20-4189-A.2020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-4189%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-4189%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immune%20infiltrate%20and%20tumor%20microenvironment%20transcriptional%20programs%20stratify%20pediatric%20osteosarcoma%20into%20prognostic%20groups%20at%20diagnosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonin%22%2C%22lastName%22%3A%22Marchais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Eugenia%22%2C%22lastName%22%3A%22Marques%20Da%20Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Job%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Drubay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Fromigu%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9dini%22%2C%22lastName%22%3A%22Fran%5Cu00e7oise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Droit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Lervat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Entz-Werle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Pacquement%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Devoldere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Cupissol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Bodet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Gandemer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20G.%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%20Marec%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Jimenez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Vassal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgit%22%2C%22lastName%22%3A%22Geoerger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Brugieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%5D%2C%22abstractNote%22%3A%22The%20outcomes%20of%20adolescents%5C%2Fyoung%20adults%20with%20osteosarcoma%20have%20not%20improved%20in%20decades.%20The%20chaotic%20karyotype%20of%20this%20rare%20tumor%20has%20precluded%20the%20identification%20of%20prognostic%20biomarkers%20and%20patient%20stratification.%20We%20reasoned%20that%20transcriptomic%20studies%20should%20overcome%20this%20genetic%20complexity.%20RNA%20sequencing%20of%2079%20osteosarcoma%20diagnostic%20biopsies%20identified%20stable%20independent%20components%20that%20recapitulate%20the%20tumor%20and%20microenvironment%20cell%20composition.%20Unsupervised%20classification%20of%20the%20independent%20components%20stratified%20this%20cohort%20into%20favorable%20%28G1%29%20and%20unfavorable%20%28G2%29%20prognostic%20tumors%20in%20terms%20of%20overall%20survival.%20Multivariate%20survival%20analysis%20ranked%20this%20stratification%20as%20the%20most%20influential%20variable.%20Functional%20characterization%20associated%20G1%20tumors%20with%20innate%20immunity%20and%20G2%20tumors%20with%20angiogenic%2C%20osteoclastic%2C%20and%20adipogenic%20activities%20as%20well%20as%20PPAR%5Cu03b3%20pathway%20upregulation.%20A%20focused%20gene%20signature%20that%20predicted%20G1%5C%2FG2%20tumors%20from%20RNA-seq%20data%20was%20developed%20and%20validated%20within%20an%20independent%20cohort%20of%2082%20osteosarcomas.%20This%20signature%20was%20further%20validated%20with%20a%20custom%20NanoString%20panel%20in%2096%20additional%20osteosarcomas.%20This%20study%20thus%20proposes%20new%20biomarkers%20to%20detect%20high-risk%20patients%20and%20new%20therapeutic%20options%20for%20osteosarcoma.%22%2C%22date%22%3A%222022-01-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F0008-5472.CAN-20-4189%22%2C%22ISSN%22%3A%221538-7445%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%223U3NWA3K%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22RAE2P5XW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daix%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDaix%2C%20Manon%2C%20Martina%20Aida%20Angeles%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Leray%2C%20Kelig%20Vergriete%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BAnterior%20Pelvic%20Exenteration%20and%20Laterally%20Extended%20Pelvic%20Resection%3A%20A%20Step%20by%20Step%20Procedure.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%201%20%28January%202022%29%3A%20107%26%23x2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-003047%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-003047%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anterior%20pelvic%20exenteration%20and%20laterally%20extended%20pelvic%20resection%3A%20a%20step%20by%20step%20procedure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelig%22%2C%22lastName%22%3A%22Vergriete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2021-003047%22%2C%22ISSN%22%3A%221525-1438%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%223U3NWA3K%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22BIL6RBHV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Akladios%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAkladios%2C%20C.%2C%20%26%23xC9%3B%20Dara%26%23xEF%3B%2C%20F.%20Golfier%2C%20F.%20Lecuru%2C%20P.%20Collinet%2C%20C.%20Uzan%2C%20V.%20Lavou%26%23xE9%3B%2C%20F.%20Guyon%2C%20G.%20Ferron%2C%20and%20D.%20Querleu.%20%26%23x201C%3B%5BA%20curriculum%20based%20certification%20of%20competence%20in%20gynaecologic%20surgical%20oncology%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologie%2C%20Obstetrique%2C%20Fertilite%20%26amp%3B%20Senologie%26lt%3B%5C%2Fi%26gt%3B%2050%2C%20no.%201%20%28January%202022%29%3A%2026%26%23x2013%3B32.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.gofs.2021.07.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.gofs.2021.07.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BA%20curriculum%20based%20certification%20of%20competence%20in%20gynaecologic%20surgical%20oncology%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Akladios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Dara%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Golfier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Lecuru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Collinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Uzan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Lavou%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Querleu%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20In%20France%2C%20we%20are%20lacking%20an%20identified%20pathway%20for%20training%20in%20gynaecological%20cancer%20surgery.%20The%20four%20competent%20French%20learned%20societies%2C%20the%20SFOG%2C%20the%20CNGOF%2C%20the%20SFCO%20and%20the%20SCGP%2C%20supported%20by%20the%20CNU%20of%20Obstetrics%20%26amp%3BGynaecology-%20and%20UNICANCER%2C%20agreed%20to%20materialize%20this%20course%20and%20attest%20it%20by%20a%20certification%20awarded%20by%20a%20national%20jury.%5CnMATERIAL%20AND%20METHODS%3A%20The%20national%20committee%20of%20certification%20in%20gynaecological%20oncology%20made%20up%20of%2010%5Cu00a0members%2C%20representing%20the%206%5Cu00a0concerned%20organizations%2C%20set%20itself%205%5Cu00a0objectives%3A%20the%20definition%20of%20the%20eligibility%20criteria%20for%20training%20centres%3B%20the%20determination%20of%20a%20check-list%20to%20be%20filled%20by%20the%20candidate%3B%20the%20determination%20of%20a%20targeted%20curriculum%20for%20the%20training%20in%20gynecological%20oncological%20surgery%3B%20the%20determination%20of%20the%20assets%20necessary%20for%20the%20certification%20of%20a%20candidate%20already%20in%20practice%3B%20and%20the%20practical%20organization%20of%20the%20certification.%5CnRESULTS%3A%20Criteria%20for%20approval%20of%20centres%20for%20training%20included%20150%5Cu00a0gynaecological%20cancer%20cases%20per%20year%2C%20among%20which%20100%5Cu00a0excisional%20surgeries%2C%20including%2020%5Cu00a0advanced-stage%20ovarian%20cancers.%20For%20certification%20of%20candidate%20who%20followed%20the%20curriculum%20established%20by%20the%20committee%20or%20by%20validation%20of%20prior%20experience%20for%20an%20actual%20practitioner%2C%20a%20candidate%20must%20validate%20a%20logbook%20and%20fill%20out%20a%20checklist%20including%204%5Cu00a0parts%3A%20theoretical%20and%20practical%20training%3B%20research%20and%20publications%3B%20teaching%20and%20subscription%20to%20a%20continuing%20education%20program.%20The%20accomplished%20elements%20of%20the%20logbook%20and%20the%20checklist%20will%20be%20evaluated%20by%20a%20score.%20The%20first%20certification%20session%20is%20planned%20for%20the%20end%20of%202021.%5CnCONCLUSION%3A%20The%20optimisation%20of%20the%20surgical%20management%20of%20patients%20treated%20for%20gynaecological%20cancer%20is%20achieved%20through%20the%20identification%20of%20a%20training%20course%20and%20the%20certification%2C%20by%20a%20national%20jury%2C%20of%20the%20skills%20of%20surgeons%20who%20have%20completed%20it.%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.gofs.2021.07.003%22%2C%22ISSN%22%3A%222468-7189%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A07Z%22%7D%7D%5D%7D
Brunac, Anne-Cécile, Joanna Fourquet, Gaëlle Perot, Marion Jaffrelot, Julie Meilleroux, Marie Danjoux, Thomas Filleron, et al. “CINSARC Signature Outperforms Gold-Standard TNM Staging and Consensus Molecular Subtypes for Clinical Outcome in Stage II-III Colorectal Carcinoma.” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, October 6, 2022. https://doi.org/10.1038/s41379-022-01166-9.
Angeles, Martina Aida, Alicia Hernández, Asunción Pérez-Benavente, Bastien Cabarrou, Emanuela Spagnolo, Agnieszka Rychlik, Amel Daboussi, et al. “The Effect of Major Postoperative Complications on Recurrence and Long-Term Survival after Cytoreductive Surgery for Ovarian Cancer.” Gynecologic Oncology 166, no. 1 (July 2022): 8–17. https://doi.org/10.1016/j.ygyno.2022.05.002.
Fayet, Yohan, Christine Chevreau, Gauthier Decanter, Cécile Dalban, Pierre Meeus, Sébastien Carrère, Leila Haddag-Miliani, et al. “No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks’ Outcome?” Cancers 14, no. 11 (May 25, 2022): 2620. https://doi.org/10.3390/cancers14112620.
Krantschenko, Emma, Paul Khayat, Aurore Siegfried, Nathalie Van Acker, and Anne Gomez-Brouchet. “[Bone-forming lesions and rearrangements of FOS genes].” Annales De Pathologie 42, no. 3 (April 2022): 208–13. https://doi.org/10.1016/j.annpat.2022.01.013.
Daix, Manon, Carlos Martinez Gomez, Martina Aida Angeles, Stéphanie Tock, Laurence Gladieff, Erwan Gabiache, Eliane Mery, Alejandra Martinez, David Cibula, and Gwénaël Ferron. “Extended Pelvic Resection for Gynecological Malignancies: A Review of out-of-the-Box Surgery.” Gynecologic Oncology, March 21, 2022, S0090-8258(22)00174-3. https://doi.org/10.1016/j.ygyno.2022.03.002.
Marchais, Antonin, Maria Eugenia Marques Da Costa, Bastien Job, Rachid Abbas, Damien Drubay, Sophie Piperno-Neumann, Olivia Fromigué, et al. “Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.” Cancer Research, January 25, 2022, canres.CAN-20-4189-A.2020. https://doi.org/10.1158/0008-5472.CAN-20-4189.
Daix, Manon, Martina Aida Angeles, Hélène Leray, Kelig Vergriete, Alejandra Martinez, and Gwenael Ferron. “Anterior Pelvic Exenteration and Laterally Extended Pelvic Resection: A Step by Step Procedure.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 32, no. 1 (January 2022): 107–8. https://doi.org/10.1136/ijgc-2021-003047.
Akladios, C., É Daraï, F. Golfier, F. Lecuru, P. Collinet, C. Uzan, V. Lavoué, F. Guyon, G. Ferron, and D. Querleu. “[A curriculum based certification of competence in gynaecologic surgical oncology].” Gynecologie, Obstetrique, Fertilite & Senologie 50, no. 1 (January 2022): 26–32. https://doi.org/10.1016/j.gofs.2021.07.003.
PUBLICATIONS 2021
7813506
CF9MRXB4
2021
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2244MCBTVI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Leray%2C%20Federico%20Migliorelli%2C%20Manon%20Daix%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BSurgical%20Approach%20of%20the%20Left%20Upper%20Quadrant%20for%20Ovarian%20Cancer%20in%2010%20Steps.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2031%2C%20no.%2011%20%28November%202021%29%3A%201488%26%23x2013%3B89.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-002963%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-002963%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Surgical%20approach%20of%20the%20left%20upper%20quadrant%20for%20ovarian%20cancer%20in%2010%20steps%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2021-002963%22%2C%22ISSN%22%3A%221525-1438%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A35Z%22%7D%7D%2C%7B%22key%22%3A%223PDW6E2I%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20Bastien%20Cabarrou%2C%20Antonio%20Gil-Moreno%2C%20Asunci%26%23xF3%3Bn%20P%26%23xE9%3Brez-Benavente%2C%20Emanuela%20Spagnolo%2C%20Agnieszka%20Rychlik%2C%20Carlos%20Mart%26%23xED%3Bnez-G%26%23xF3%3Bmez%2C%20et%20al.%20%26%23x201C%3BEffect%20of%20Tumor%20Burden%20and%20Radical%20Surgery%20on%20Survival%20Difference%20between%20Upfront%2C%20Early%20Interval%20or%20Delayed%20Cytoreductive%20Surgery%20in%20Ovarian%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Gynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%206%20%28November%202021%29%3A%20e78.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3802%5C%2Fjgo.2021.32.e78%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3802%5C%2Fjgo.2021.32.e78%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20tumor%20burden%20and%20radical%20surgery%20on%20survival%20difference%20between%20upfront%2C%20early%20interval%20or%20delayed%20cytoreductive%20surgery%20in%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil-Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asunci%5Cu00f3n%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Benavente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Spagnolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnieszka%22%2C%22lastName%22%3A%22Rychlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignacio%22%2C%22lastName%22%3A%22Zapardiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Illac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22B%5Cu00e9trian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20We%20sought%20to%20evaluate%20the%20impact%20on%20survival%20of%20tumor%20burden%20and%20surgical%20complexity%20in%20relation%20to%20the%20number%20of%20cycles%20of%20neoadjuvant%20chemotherapy%20%28NACT%29%20in%20patients%20with%20advanced%20ovarian%20cancer%20%28OC%29%20with%20minimal%20%28CC-1%29%20or%20no%20residual%20disease%20%28CC-0%29.%5CnMETHODS%3A%20This%20retrospective%20study%20included%20patients%20with%20International%20Federation%20of%20Gynaecology%20and%20Obstetrics%20IIIC-IV%20stage%20OC%20who%20underwent%20debulking%20surgery%20at%204%20high-volume%20institutions%20between%20January%202008%20and%20December%202015.%20We%20assessed%20the%20overall%20survival%20%28OS%29%20of%20primary%20debulking%20surgery%20%28PDS%20group%29%2C%20early%20interval%20debulking%20surgery%20after%203-4%20cycles%20of%20NACT%20%28early%20IDS%20group%29%20and%20delayed%20debulking%20surgery%20after%206%20cycles%20%28DDS%20group%29%20with%20CC-0%20or%20CC-1%20according%20to%20peritoneal%20cancer%20index%20%28PCI%29%20and%20Aletti%20score.%5CnRESULTS%3A%20Five%20hundred%20forty-nine%20women%20were%20included%3A%20175%20%2831.9%25%29%20had%20PDS%2C%20224%20%2840.8%25%29%20early%20IDS%20and%20150%20%2827.3%25%29%20DDS.%20Regardless%20of%20Aletti%20score%2C%20median%20OS%20after%20PDS%20was%20significantly%20higher%20than%20after%20early%20IDS%20or%20DDS%2C%20but%20the%20survival%20difference%20was%20higher%20in%20women%20with%20an%20Aletti%20score%20%26lt%3B8.%20Among%20patients%20with%20PCI%20%5Cu226410%2C%20median%20OS%20after%20PDS%20was%20significantly%20higher%20than%20after%20early%20IDS%20or%20DDS.%20In%20women%20with%20PCI%20%26gt%3B10%2C%20there%20were%20no%20differences%20between%20PDS%20and%20early%20IDS%2C%20but%20DDS%20was%20associated%20with%20decreased%20OS.%5CnCONCLUSION%3A%20The%20benefit%20of%20complete%20PDS%20compared%20with%20NACT%20was%20maximal%20in%20patients%20with%20a%20low%20complexity%20score.%20In%20patients%20with%20low%20tumor%20burden%2C%20there%20was%20a%20survival%20benefit%20of%20PDS%20over%20early%20IDS%20or%20DDS.%20In%20women%20with%20high%20tumor%20load%2C%20DDS%20impaired%20the%20oncological%20outcome.%22%2C%22date%22%3A%222021-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3802%5C%2Fjgo.2021.32.e78%22%2C%22ISSN%22%3A%222005-0399%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-01-14T15%3A43%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22NHQK465D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brito%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrito%2C%20Ariadna%2C%20Candice%20Merle%2C%20Pauline%20Lagarde%2C%20Benjamin%20Faustin%2C%20Anne%20Devin%2C%20Lydia%20Lartigue%2C%20and%20Frederic%20Chibon.%20%26%23x201C%3BCell%20Fusion%20Enhances%20Energy%20Metabolism%20of%20Mesenchymal%20Tumor%20Hybrid%20Cells%20to%20Sustain%20Their%20Proliferation%20and%20Invasion.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2021%2C%20no.%201%20%28July%2028%2C%202021%29%3A%20863.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-08561-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-08561-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cell%20fusion%20enhances%20energy%20metabolism%20of%20mesenchymal%20tumor%20hybrid%20cells%20to%20sustain%20their%20proliferation%20and%20invasion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariadna%22%2C%22lastName%22%3A%22Brito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Faustin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Devin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cell-to-cell%20fusion%20is%20emerging%20as%20a%20key%20element%20of%20the%20metastatic%20process%20in%20various%20cancer%20types.%20We%20recently%20showed%20that%20hybrids%20made%20from%20the%20spontaneous%20merging%20of%20pre-malignant%20%28IMR90%20E6E7%2C%20i.e.%20E6E7%29%20and%20malignant%20%28IMR90%20E6E7%20RST%2C%20i.e.%20RST%29%20mesenchymal%20cells%20recapitulate%20the%20main%20features%20of%20human%20undifferentiated%20pleomorphic%20sarcoma%20%28UPS%29%2C%20with%20a%20highly%20rearranged%20genome%20and%20increased%20spreading%20capacities.%20To%20better%20characterize%20the%20intrinsic%20properties%20of%20these%20hybrids%2C%20we%20investigated%20here%20their%20metabolic%20energy%20profile%20compared%20to%20their%20parents.%5CnRESULTS%3A%20Our%20results%20unveiled%20that%20hybrids%20harbored%20a%20Warburg-like%20metabolism%2C%20like%20their%20RST%20counterparts.%20However%2C%20hybrids%20displayed%20a%20much%20greater%20metabolic%20activity%2C%20enhancing%20glycolysis%20to%20proliferate.%20Interestingly%2C%20modifying%20the%20metabolic%20environmental%20conditions%20through%20the%20use%20of%205-aminoimidazole-4-carbox-amide-1-%5Cu03b2-D-ribofuranoside%20%28AICAR%29%2C%20an%20activator%20of%20the%205%26%23039%3B-adenosine%20monophosphate%20%28AMP%29-activated%20protein%20kinase%20%28AMPK%29%2C%20specifically%20reduced%20the%20growth%20of%20hybrids%2C%20and%20also%20abrogated%20the%20invasive%20capacity%20of%20hybrids%20displaying%20enhanced%20glycolysis.%20Furthermore%2C%20AICAR%20efficiently%20blocked%20the%20tumoral%20features%20related%20to%20the%20aggressiveness%20of%20human%20UPS%20cell%20lines.%5CnCONCLUSION%3A%20Altogether%2C%20our%20findings%20strongly%20suggest%20that%20hybrids%20rely%20on%20higher%20energy%20flux%20to%20proliferate%20and%20that%20a%20drug%20altering%20this%20metabolic%20equilibrium%20could%20impair%20their%20survival%20and%20be%20potentially%20considered%20as%20a%20novel%20therapeutic%20strategy.%22%2C%22date%22%3A%222021-07-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-021-08561-6%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A31%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22S4ZM5NII%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Beddok%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBeddok%2C%20Arnaud%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Sophie%20Le%20Guellec%2C%20No%26%23xE9%3Bmie%20Thebault%2C%20Alexandre%20Coutte%2C%20Henri%20Sevestre%2C%20Bruno%20Chauffert%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BGerminal%20GLT8D1%2C%20GATAD2A%20and%20SLC25A39%20Mutations%20in%20a%20Patient%20with%20a%20Glomangiopericytal%20Tumor%20and%20Five%20Different%20Sarcomas%20over%20a%2010-Year%20Period.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScientific%20Reports%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%201%20%28May%207%2C%202021%29%3A%209765.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-88671-0%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-88671-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Germinal%20GLT8D1%2C%20GATAD2A%20and%20SLC25A39%20mutations%20in%20a%20patient%20with%20a%20glomangiopericytal%20tumor%20and%20five%20different%20sarcomas%20over%20a%2010-year%20period%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Beddok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Thebault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Coutte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Sevestre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Chauffert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Soft%20tissue%20sarcoma%20represents%20about%201%25%20of%20all%20adult%20cancers.%20Occurrence%20of%20multiple%20sarcomas%20in%20a%20same%20individual%20cannot%20be%20fortuitous.%20A%2072-year-old%20patient%20had%20between%202007%20and%202016%20a%20glomangiopericytal%20tumor%20of%20the%20right%20forearm%20and%20a%20succession%20of%20sarcomas%20of%20the%20extremities%3A%20a%20leiomyosarcoma%20of%20the%20left%20buttock%2C%20a%20myxofibrosarcoma%20%28MFS%29%20of%20the%20right%20forearm%2C%20a%5Cu00a0MFS%20of%20the%20left%20scapula%2C%20a%20left%20latero-thoracic%20MFS%20and%20two%20undifferentiated%20sarcomas%20on%20the%20left%20forearm.%20Pathological%20examination%20of%20the%20six%20locations%20was%20not%20in%20favor%20of%20disease%20with%20local%5C%2Fdistant%20recurrences%20but%20could%20not%20confirm%20different%20diseases.%20An%20extensive%20molecular%20analysis%20including%20DNA-array%2C%20RNA-sequencing%20and%20DNA-Sanger-sequencing%2C%20was%20thus%20performed%20to%20determine%20the%20link%20between%20them.%20The%20genomic%20profile%20of%20the%20glomangiopericytal%20tumor%20and%20the%20six%20sarcomas%20revealed%20that%20five%20sarcomas%20were%20different%20diseases%20and%20one%20was%20the%20local%20recurrence%20of%20the%20glomangiopericytal%20tumor.%20While%20the%20chromosomal%20alterations%20in%20the%20six%20tumors%20were%20different%2C%20a%20common%20somatic%20CDKN2A%5C%2FCDKN2B%20deletion%20was%20identified.%20RNA-sequencing%20of%20five%20tumors%20identified%20mutations%20in%20GLT8D1%2C%20GATAD2A%20and%20SLC25A39%20in%20all%20samples.%20The%20germline%20origin%20of%20these%20mutations%20was%20confirmed%20by%20Sanger-sequencing.%20Innovative%20molecular%20analysis%20methods%20have%20made%20possible%20a%20better%20understanding%20of%20the%20complex%20tumorigenesis%20of%20multiple%20sarcomas.%22%2C%22date%22%3A%222021-05-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-88671-0%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A26%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22G3FX4ST6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Darmusey%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDarmusey%2C%20Lucie%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Sophie%20Le%20Guellec%2C%20Nelly%20Desplat%2C%20La%26%23xEB%3Btitia%20Gaston%2C%20Lucile%20Delespaul%2C%20et%20al.%20%26%23x201C%3BATRX%20Alteration%20Contributes%20to%20Tumor%20Growth%20and%20Immune%20Escape%20in%20Pleomorphic%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2013%2C%20no.%209%20%28April%2029%2C%202021%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13092151%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13092151%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ATRX%20Alteration%20Contributes%20to%20Tumor%20Growth%20and%20Immune%20Escape%20in%20Pleomorphic%20Sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Darmusey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Desplat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22La%5Cu00ebtitia%22%2C%22lastName%22%3A%22Gaston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Darbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Richard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Whole%20genome%20and%20transcriptome%20sequencing%20of%20a%20cohort%20of%2067%20leiomyosarcomas%20has%20been%20revealed%20ATRX%20to%20be%20one%20of%20the%20most%20frequently%20mutated%20genes%20in%20leiomyosarcomas%20after%20TP53%20and%20RB1.%20While%20its%20function%20is%20well%20described%20in%20the%20alternative%20lengthening%20of%20telomeres%20mechanism%2C%20we%20wondered%20whether%20its%20alteration%20could%20have%20complementary%20effects%20on%20sarcoma%20oncogenesis.%20ATRX%20alteration%20is%20associated%20with%20the%20down-expression%20of%20genes%20linked%20to%20differentiation%20in%20leiomyosarcomas%2C%20and%20to%20immunity%20in%20an%20additional%20cohort%20of%2060%20poorly%20differentiated%20pleomorphic%20sarcomas.%20In%20vitro%20and%20in%20vivo%20models%20showed%20that%20ATRX%20down-expression%20increases%20tumor%20growth%20rate%20and%20immune%20escape%20by%20decreasing%20the%20immunity%20load%20of%20active%20mast%20cells%20in%20sarcoma%20tumors.%20These%20data%20indicate%20that%20an%20alternative%20to%20unsuccessful%20targeting%20of%20the%20adaptive%20immune%20system%20in%20sarcoma%20could%20target%20the%20innate%20system.%20This%20might%20lead%20to%20a%20better%20outcome%20for%20sarcoma%20patients%20in%20terms%20of%20ATRX%20status.%22%2C%22date%22%3A%222021-04-29%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13092151%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A53%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22PKFEBRGX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brahmi%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrahmi%2C%20M.%2C%20T.%20Lesluyes%2C%20A.%20Dufresne%2C%20M.%20Toulmonde%2C%20A.%20Italiano%2C%20O.%20Mir%2C%20A.%20Le%20Cesne%2C%20et%20al.%20%26%23x201C%3BExpression%20and%20Prognostic%20Significance%20of%20PDGF%20Ligands%20and%20Receptors%20across%20Soft%20Tissue%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BESMO%20Open%26lt%3B%5C%2Fi%26gt%3B%206%2C%20no.%201%20%28February%202021%29%3A%20100037.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2020.100037%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2020.100037%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expression%20and%20prognostic%20significance%20of%20PDGF%20ligands%20and%20receptors%20across%20soft%20tissue%20sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Mir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-M.%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-Y.%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20the%20anti-PDGFRA%20antibody%20olaratumab%20failed%20to%20confirm%20an%20impact%20on%20survival%20in%20unselected%20advanced%20soft%20tissue%20sarcoma%20%28STS%29%20patients%2C%20the%20level%20of%20expression%20and%20the%20prognosis%20of%20platelet-derived%20growth%20factor%20%28PDGF%29%20receptors%20and%20ligands%20in%20STS%20remain%20unclear.%5CnPATIENTS%20AND%20METHODS%3A%20We%20analyzed%20PDGF%20ligands%20and%20receptors%26%23039%3B%20expression%20levels%20in%20a%20series%20of%20255%20patients%20with%20different%20histologies%20of%20STS%20%5Bgastrointestinal%20stromal%20tumor%20%28GIST%29%2C%20myxoid%20liposarcoma%20%28MLPS%29%2C%20sarcoma%20with%20complex%20genomics%2C%20synovial%20sarcoma%20%28SyS%29%5D%20with%20Agilent%20single-color%20micro-arrays.%20We%20explored%20expression%20levels%20as%20prognostic%20values%20in%20univariate%20and%20multivariate%20analysis%20using%20R%20software%20%28version%203.4.2%29.%5CnRESULTS%3A%20Complex%20patterns%20of%20correlation%20of%20expression%20between%20ligands%20and%20receptors%20were%20observed%20for%20each%20histotype.%20PDGFA%20levels%20were%20highest%20in%20SyS%20and%20lowest%20in%20MLPS%20%28P%20%26lt%3B%204%5Cu00a0%5Cu00d7%2010-9%29%2C%20PDGFB%20and%20C%20levels%20were%20lower%20in%20GIST%20%28P%20%26lt%3B%202%5Cu00a0%5Cu00d7%2010-15%20and%20P%20%26lt%3B%203%5Cu00a0%5Cu00d7%2010-9%29%20while%20PDGFD%20expression%20was%20similar%20across%20histological%20subtypes.%20PDGF%20receptor%20%28PDGFR%29%20A%20expression%20was%20lowest%20in%20MLPS%20%28P%20%26lt%3B%200.002%29%2C%20whereas%20PDGFRB%20and%20L%20expressions%20were%20lowest%20in%20GIST%20and%20SyS%20%28P%20%26lt%3B%200.0004%29.%20Interestingly%2C%20high%20PDGFA%20expression%20levels%20were%20associated%20with%20higher%20risk%20of%20metastasis%20%28P%5Cu00a0%3D%200.006%29%2C%20whereas%20PDGFD%20levels%20above%20average%20were%20associated%20with%20a%20reduced%20risk%20of%20metastasis%20%28P%5Cu00a0%3D%200.01%29%20in%20univariate%20and%20multivariate%20analysis.%5CnCONCLUSIONS%3A%20The%20expression%20of%20PDGF%20ligands%20and%20receptors%20varies%20across%20sarcoma%20histological%20subtypes.%20PDGFA%20and%20D%20expression%20levels%20independently%20and%20inversely%20correlate%20with%20the%20risk%20of%20metastatic%20relapse.%22%2C%22date%22%3A%222021-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2020.100037%22%2C%22ISSN%22%3A%222059-7029%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A26%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22CAQMXBP4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Merle%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMerle%2C%20Candice%2C%20Pauline%20Lagarde%2C%20Lydia%20Lartigue%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BAcquisition%20of%20Cancer%20Stem%20Cell%20Capacities%20after%20Spontaneous%20Cell%20Fusion.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2021%2C%20no.%201%20%282021%29%3A%20241.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-07979-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-07979-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acquisition%20of%20cancer%20stem%20cell%20capacities%20after%20spontaneous%20cell%20fusion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Cancer%20stem%5C%2FInitiating%20cell%20%28CS%5C%2FIC%29%20hypothesis%20argues%20that%20CS%5C%2FICs%20are%20responsible%20of%20tumour%20initiation%2C%20drug%20resistance%2C%20metastasis%20or%20disease%20relapse.%20Their%20detection%20in%20several%20cancers%20supports%20this%20concept.%20However%2C%20their%20origin%20is%20still%20misunderstood.%20Cell%20fusion%20is%20shown%20to%20take%20part%20in%20the%20formation%20of%20CS%5C%2FICs%2C%20i.e.%20fusion%20between%20mesenchymal%20stem%20cell%20and%20cancer%20cell.%20In%20a%20previous%20paper%2C%20we%20described%20that%20fusion%20leads%20to%20hybrids%20with%20metastatic%20capacity.%20This%20process%20triggered%20genomic%20rearrangements%20in%20hybrid%20cells%20together%20with%20increased%20metastasis%20development.%20Here%2C%20we%20hypothesize%20that%20cell%20fusion%20could%20be%20strong%20enough%20to%20provoke%20a%20cellular%20reprogramming%20and%20the%20acquisition%20of%20CS%5C%2FIC%20properties%2C%20promoting%20metastasis%20formation.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20spontaneous%20cell%20fusion%20between%20E6E7%20%28IMR90%20with%20the%20oncogenes%20E6%20and%20E7%29%20and%20RST%20%28IMR90%20fully%20transformed%29%20cell%20lines%2C%20hybrid%20cells%20were%20selected%20by%20dual%20antibiotic%20selection.%20Cancer%20stem%20cells%20capacities%20were%20evaluated%20regarding%20capacity%20to%20form%20spheres%2C%20expression%20of%20stem%20cell%20markers%20and%20the%20presence%20of%20ALDH%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20high%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20cells.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Our%20data%20show%20that%20after%20cell%20fusion%2C%20all%20hybrids%20contain%20a%20percentage%20of%20cells%20with%20CS%5C%2FICs%20properties%2C%20regarding.%20Importantly%2C%20we%20lastly%20showed%20that%20NANOG%20inhibition%20in%20H1%20hybrid%20decreases%20this%20migration%20capacity%20while%20having%20no%20effect%20on%20the%20corresponding%20parental%20cells.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Altogether%20these%20results%20indicate%20that%20the%20combination%20of%20CS%5C%2FICs%20properties%20and%20genomic%20rearrangement%20in%20hybrids%20is%20likely%20to%20be%20key%20to%20tumour%20progression.%22%2C%22date%22%3A%2212%5C%2F2021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-021-07979-2%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbmccancer.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs12885-021-07979-2%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-01-28T15%3A06%3A24Z%22%7D%7D%5D%7D
Angeles, Martina Aida, Hélène Leray, Federico Migliorelli, Manon Daix, Alejandra Martinez, and Gwenael Ferron. “Surgical Approach of the Left Upper Quadrant for Ovarian Cancer in 10 Steps.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 31, no. 11 (November 2021): 1488–89. https://doi.org/10.1136/ijgc-2021-002963.
Angeles, Martina Aida, Bastien Cabarrou, Antonio Gil-Moreno, Asunción Pérez-Benavente, Emanuela Spagnolo, Agnieszka Rychlik, Carlos Martínez-Gómez, et al. “Effect of Tumor Burden and Radical Surgery on Survival Difference between Upfront, Early Interval or Delayed Cytoreductive Surgery in Ovarian Cancer.” Journal of Gynecologic Oncology 32, no. 6 (November 2021): e78. https://doi.org/10.3802/jgo.2021.32.e78.
Brito, Ariadna, Candice Merle, Pauline Lagarde, Benjamin Faustin, Anne Devin, Lydia Lartigue, and Frederic Chibon. “Cell Fusion Enhances Energy Metabolism of Mesenchymal Tumor Hybrid Cells to Sustain Their Proliferation and Invasion.” BMC Cancer 21, no. 1 (July 28, 2021): 863. https://doi.org/10.1186/s12885-021-08561-6.
Beddok, Arnaud, Gaëlle Pérot, Sophie Le Guellec, Noémie Thebault, Alexandre Coutte, Henri Sevestre, Bruno Chauffert, and Frédéric Chibon. “Germinal GLT8D1, GATAD2A and SLC25A39 Mutations in a Patient with a Glomangiopericytal Tumor and Five Different Sarcomas over a 10-Year Period.” Scientific Reports 11, no. 1 (May 7, 2021): 9765. https://doi.org/10.1038/s41598-021-88671-0.
Darmusey, Lucie, Gaëlle Pérot, Noémie Thébault, Sophie Le Guellec, Nelly Desplat, Laëtitia Gaston, Lucile Delespaul, et al. “ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas.” Cancers 13, no. 9 (April 29, 2021). https://doi.org/10.3390/cancers13092151.
Brahmi, M., T. Lesluyes, A. Dufresne, M. Toulmonde, A. Italiano, O. Mir, A. Le Cesne, et al. “Expression and Prognostic Significance of PDGF Ligands and Receptors across Soft Tissue Sarcomas.” ESMO Open 6, no. 1 (February 2021): 100037. https://doi.org/10.1016/j.esmoop.2020.100037.
Merle, Candice, Pauline Lagarde, Lydia Lartigue, and Frédéric Chibon. “Acquisition of Cancer Stem Cell Capacities after Spontaneous Cell Fusion.” BMC Cancer 21, no. 1 (2021): 241. https://doi.org/10.1186/s12885-021-07979-2.
PUBLICATIONS 2020
7813506
CF9MRXB4
2020
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22TABWS96W%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Croce%20and%20Chibon%22%2C%22parsedDate%22%3A%222020-11-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCroce%2C%20Sabrina%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BMolecular%20Prognostication%20of%20Uterine%20Smooth%20Muscle%20Neoplasms%3A%20From%20%26lt%3Bspan%20style%3D%26quot%3Bfont-variant%3Asmall-caps%3B%26quot%3B%26gt%3BCGH%26lt%3B%5C%2Fspan%26gt%3B%20Array%20to%20%26lt%3Bspan%20style%3D%26quot%3Bfont-variant%3Asmall-caps%3B%26quot%3B%26gt%3BCINSARC%26lt%3B%5C%2Fspan%26gt%3B%20Signature%20and%20Beyond.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGenes%2C%20Chromosomes%20and%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2011%2C%202020%2C%20gcc.22906.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22906%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22906%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20prognostication%20of%20uterine%20smooth%20muscle%20neoplasms%3A%20From%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3ECGH%3C%5C%2Fspan%3E%20array%20to%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3ECINSARC%3C%5C%2Fspan%3E%20signature%20and%20beyond%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Croce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-11-11%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fgcc.22906%22%2C%22ISSN%22%3A%221045-2257%2C%201098-2264%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1002%5C%2Fgcc.22906%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A52Z%22%7D%7D%2C%7B%22key%22%3A%223V3C7KTP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesluyes%20and%20Chibon%22%2C%22parsedDate%22%3A%222020-10-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLesluyes%2C%20Tom%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BA%20Global%20and%20Integrated%20Analysis%20of%20CINSARC-Associated%20Genetic%20Defects.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20October%206%2C%202020%2C%20canres.0512.2020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-0512%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-0512%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20global%20and%20integrated%20analysis%20of%20CINSARC-associated%20genetic%20defects%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10-06%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F0008-5472.CAN-20-0512%22%2C%22ISSN%22%3A%220008-5472%2C%201538-7445%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcancerres.aacrjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1158%5C%2F0008-5472.CAN-20-0512%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A43Z%22%7D%7D%2C%7B%22key%22%3A%225SZSN86F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ciss%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCiss%26%23xE9%3B%2C%20Madi%20Y.%2C%20Samuel%20Pyrdziak%2C%20Nelly%20Firmin%2C%20Laurie%20Gayte%2C%20Maud%20Heuillet%2C%20Floriant%20Bellvert%2C%20Maryse%20Fuentes%2C%20et%20al.%20%26%23x201C%3BTargeting%20MDM2-Dependent%20Serine%20Metabolism%20as%20a%20Therapeutic%20Strategy%20for%20Liposarcoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScience%20Translational%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%20547%20%28June%2010%2C%202020%29%3A%20eaay2163.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.aay2163%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.aay2163%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeting%20MDM2-dependent%20serine%20metabolism%20as%20a%20therapeutic%20strategy%20for%20liposarcoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madi%20Y.%22%2C%22lastName%22%3A%22Ciss%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Pyrdziak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurie%22%2C%22lastName%22%3A%22Gayte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Heuillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floriant%22%2C%22lastName%22%3A%22Bellvert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryse%22%2C%22lastName%22%3A%22Fuentes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Delpech%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Riscal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Arena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Gellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Maran-Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Chateau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Theillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Carrere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Charles%22%2C%22lastName%22%3A%22Portais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Le%20Cam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%20K.%22%2C%22lastName%22%3A%22Linares%22%7D%5D%2C%22abstractNote%22%3A%22Well-differentiated%20and%20dedifferentiated%20liposarcomas%20%28LPSs%29%20are%20characterized%20by%20a%20systematic%20amplification%20of%20the%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20MDM2%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20oncogene%2C%20which%20encodes%20a%20key%20negative%20regulator%20of%20the%20p53%20pathway.%20The%20molecular%20mechanisms%20underlying%20MDM2%20overexpression%20while%20sparing%20wild-type%20p53%20in%20LPS%20remain%20poorly%20understood.%20Here%2C%20we%20show%20that%20the%20p53-independent%20metabolic%20functions%20of%20chromatin-bound%20MDM2%20are%20exacerbated%20in%20LPS%20and%20mediate%20an%20addiction%20to%20serine%20metabolism%20that%20sustains%20nucleotide%20synthesis%20and%20tumor%20growth.%20Treatment%20of%20LPS%20cells%20with%20Nutlin-3A%2C%20a%20pharmacological%20inhibitor%20of%20the%20MDM2-p53%20interaction%2C%20stabilized%20p53%20but%20unexpectedly%20enhanced%20MDM2-mediated%20control%20of%20serine%20metabolism%20by%20increasing%20its%20recruitment%20to%20chromatin%2C%20likely%20explaining%20the%20poor%20clinical%20efficacy%20of%20this%20class%20of%20MDM2%20inhibitors.%20In%20contrast%2C%20genetic%20or%20pharmacological%20inhibition%20of%20chromatin-bound%20MDM2%20by%20SP141%2C%20a%20distinct%20MDM2%20inhibitor%20triggering%20its%20degradation%2C%20or%20interfering%20with%20de%20novo%20serine%20synthesis%2C%20impaired%20LPS%20growth%20both%20in%20vitro%20and%20in%20clinically%20relevant%20patient-derived%20xenograft%20models.%20Our%20data%20indicate%20that%20targeting%20MDM2%20functions%20in%20serine%20metabolism%20represents%20a%20potential%20therapeutic%20strategy%20for%20LPS.%22%2C%22date%22%3A%222020-06-10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1126%5C%2Fscitranslmed.aay2163%22%2C%22ISSN%22%3A%221946-6234%2C%201946-6242%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fstm.sciencemag.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1126%5C%2Fscitranslmed.aay2163%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22CCJT38SX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Merle%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMerle%2C%20Candice%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Sophie%20LeGuellec%2C%20Jessica%20Baud%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Tom%20Lesluyes%2C%20Lucile%20Delespaul%2C%20Lydia%20Lartigue%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BTetraploidization%20of%20Immortalized%20Myoblasts%20Induced%20by%20Cell%20Fusion%20Drives%20Myogenic%20Sarcoma%20Development%20with%20DMD%20Deletion.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%205%20%28May%2019%2C%202020%29%3A%201281.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12051281%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12051281%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tetraploidization%20of%20Immortalized%20Myoblasts%20Induced%20by%20Cell%20Fusion%20Drives%20Myogenic%20Sarcoma%20Development%20with%20DMD%20Deletion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22LeGuellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Whole-genome%20doubling%20is%20the%20second%20most%20frequent%20genomic%20event%2C%20after%20TP53%20alterations%2C%20in%20advanced%20solid%20tumors%20and%20is%20associated%20with%20poor%20prognosis.%20Tetraploidization%20step%20will%20lead%20to%20aneuploidy%20and%20chromosomic%20rearrangements.%20The%20mechanism%20leading%20to%20tetraploid%20cells%20is%20important%20since%20endoreplication%2C%20abortive%20cytokinesis%20and%20cell%20fusion%20could%20have%20distinct%20consequences.%20Unlike%20processes%20based%20on%20duplication%2C%20cell%20fusion%20involves%20the%20merging%20of%20two%20different%20genomes%2C%20epigenomes%20and%20cellular%20states.%20Since%20it%20is%20involved%20in%20muscle%20differentiation%2C%20we%20hypothesized%20that%20it%20could%20play%20a%20role%20in%20the%20oncogenesis%20of%20myogenic%20cancers.%20Spontaneous%20hybrids%2C%20but%20not%20their%20non-fused%20immortalized%20myoblast%20counterparts%20they%20are%20generated%20from%2C%20induced%20tumors%20in%20mice.%20Unstable%20upon%20fusion%2C%20the%20hybrid%20genome%20evolved%20from%20initial%20mitosis%20to%20tumors%20with%20a%20highly%20rearranged%20genome.%20This%20genome%20remodeling%20finally%20produced%20targeted%20DMD%20deletions%20associated%20with%20replicative%20stress%2C%20isoform%20relocalization%20and%20metastatic%20spreading%2C%20exactly%20as%20observed%20in%20human%20myogenic%20sarcomas.%20In%20conclusion%2C%20these%20results%20draw%20a%20model%20of%20myogenic%20oncogenesis%20in%20which%20cell%20fusion%20and%20oncogene%20activation%20combine%20to%20produce%20pleomorphic%20aggressive%20sarcomas.%22%2C%22date%22%3A%222020-05-19%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12051281%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F5%5C%2F1281%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22MSEX8BXI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lartigue%20et%20al.%22%2C%22parsedDate%22%3A%222020-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLartigue%2C%20Lydia%2C%20Candice%20Merle%2C%20Pauline%20Lagarde%2C%20Lucile%20Delespaul%2C%20Tom%20Lesluyes%2C%20Sophie%20Le%20Guellec%2C%20Gaelle%20P%26%23xE9%3Brot%2C%20Laura%20Leroy%2C%20Jean-Michel%20Coindre%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BGenome%20Remodeling%20upon%20Mesenchymal%20Tumor%20Cell%20Fusion%20Contributes%20to%20Tumor%20Progression%20and%20Metastatic%20Spread.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncogene%26lt%3B%5C%2Fi%26gt%3B%2039%2C%20no.%2021%20%28May%202020%29%3A%204198%26%23x2013%3B4211.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-020-1276-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-020-1276-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Genome%20remodeling%20upon%20mesenchymal%20tumor%20cell%20fusion%20contributes%20to%20tumor%20progression%20and%20metastatic%20spread%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaelle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Cell%20fusion%20in%20tumor%20progression%20mostly%20refers%20to%20the%20merging%20of%20a%20cancer%20cell%20with%20a%20cell%20that%20has%20migration%20and%20immune%20escape%20capabilities%20such%20as%20macrophages.%20Here%20we%20show%20that%20spontaneous%20hybrids%20made%20from%20the%20fusion%20of%20transformed%20mesenchymal%20cells%20with%20partners%20from%20the%20same%20lineage%20undergo%20nonrecurrent%20large-scale%20genomic%20rearrangements%2C%20leading%20to%20the%20creation%20of%20highly%20aneuploid%20cells%20with%20novel%20phenotypic%20traits%2C%20including%20metastatic%20spreading%20capabilities.%20Moreover%2C%20in%20contrast%20to%20their%20parents%2C%20hybrids%20were%20the%20only%20cells%20able%20to%20recapitulate%20in%20vivo%20all%20features%20of%20human%20pleomorphic%20sarcomas%2C%20a%20rare%20and%20genetically%20complex%20mesenchymal%20tumor.%20Hybrid%20tumors%20not%20only%20displayed%20specific%20mesenchymal%20markers%2C%20but%20also%20combined%20a%20complex%20genetic%20profile%20with%20a%20highly%20metastatic%20behavior%2C%20like%20their%20human%20counterparts.%20Finally%2C%20we%20provide%20evidence%20that%20patient-derived%20pleomorphic%20sarcoma%20cells%20are%20inclined%20to%20spontaneous%20cell%20fusion.%20The%20resulting%20hybrids%20also%20gain%20in%20aggressiveness%2C%20exhibiting%20superior%20growth%20capacity%20in%20mouse%20models.%20Altogether%2C%20these%20results%20indicate%20that%20cell%20fusion%20has%20the%20potential%20to%20promote%20cancer%20progression%20by%20increasing%20growth%20and%5C%2For%20metastatic%20capacities%2C%20regardless%20of%20the%20nature%20of%20the%20companion%20cell.%20Moreover%2C%20such%20events%20likely%20occur%20upon%20sarcoma%20development%2C%20paving%20the%20way%20for%20better%20understanding%20of%20the%20biology%2C%20and%20aggressiveness%20of%20these%20tumors.%22%2C%22date%22%3A%22May%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41388-020-1276-6%22%2C%22ISSN%22%3A%221476-5594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22M7Y7A7GS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mattei%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMattei%2C%20Jean%20Camille%2C%20Corinne%20Bouvier-Labit%2C%20Doriane%20Barets%2C%20Nicolas%20Macagno%2C%20Mathieu%20Chocry%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon%2C%20Philippe%20Morando%2C%20et%20al.%20%26%23x201C%3BPan%20Aurora%20Kinase%20Inhibitor%3A%20A%20Promising%20Targeted-Therapy%20in%20Dedifferentiated%20Liposarcomas%20With%20Differential%20Efficiency%20Depending%20on%20Sarcoma%20Molecular%20Profile.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%203%20%28March%203%2C%202020%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12030583%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12030583%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pan%20Aurora%20Kinase%20Inhibitor%3A%20A%20Promising%20Targeted-Therapy%20in%20Dedifferentiated%20Liposarcomas%20With%20Differential%20Efficiency%20Depending%20on%20Sarcoma%20Molecular%20Profile%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Camille%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Bouvier-Labit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doriane%22%2C%22lastName%22%3A%22Barets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Macagno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Chocry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Morando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20Alexandre%22%2C%22lastName%22%3A%22Rochwerger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Duffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylviane%22%2C%22lastName%22%3A%22Olschwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Salas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Jiguet-Jiglaire%22%7D%5D%2C%22abstractNote%22%3A%22Soft%20tissue%20sarcoma%20%28STS%29%20are%20rare%20and%20aggressive%20tumours.%20Their%20classification%20includes%20numerous%20histological%20subtypes%20of%20frequent%20poor%20prognosis.%20Liposarcomas%20%28LPS%29%20are%20the%20most%20frequent%20type%20among%20them%2C%20and%20the%20aggressiveness%20and%20deep%20localization%20of%20dedifferentiated%20LPS%20are%20linked%20to%20high%20levels%20of%20recurrence.%20Current%20treatments%20available%20today%20lead%20to%20five-year%20overall%20survival%20has%20remained%20stuck%20around%2060%25-70%25%20for%20the%20past%20three%20decades.%20Here%2C%20we%20highlight%20a%20correlation%20between%20Aurora%20kinasa%20A%20%28AURKA%29%20and%20AURKB%20mRNA%20overexpression%20and%20a%20low%20metastasis%20-%20free%20survival.%20AURKA%20and%20AURKB%20expression%20analysis%20at%20genomic%20and%20protein%20level%20on%20a%209-STS%20cell%20lines%20panel%20highlighted%20STS%20heterogeneity%2C%20especially%20in%20LPS%20subtype.%20AURKA%20and%20AURKB%20inhibition%20by%20RNAi%20and%20drug%20targeting%20with%20AMG%20900%2C%20a%20pan%20Aurora%20Kinase%20inhibitor%2C%20in%20four%20LPS%20cell%20lines%20reduces%20cell%20survival%20and%20clonogenic%20proliferation%2C%20inducing%20apoptosis%20and%20polyploidy.%20When%20combined%20with%20doxorubicin%2C%20the%20standard%20treatment%20in%20STS%2C%20aurora%20kinases%20inhibitor%20can%20be%20considered%20as%20an%20enhancer%20of%20standard%20treatment%20or%20as%20an%20independent%20drug.%20Kinome%20analysis%20suggested%20its%20effect%20was%20linked%20to%20the%20inhibition%20of%20the%20MAP-kinase%20pathway%2C%20with%20differential%20drug%20resistance%20profiles%20depending%20on%20molecular%20characteristics%20of%20the%20tumor.%20Aurora%20Kinase%20inhibition%20by%20AMG%20900%20could%20be%20a%20promising%20therapy%20in%20STS.%22%2C%22date%22%3A%22Mar%2003%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12030583%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22DZ6IZI2A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jakob%20et%20al.%22%2C%22parsedDate%22%3A%222020-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJakob%2C%20Jens%2C%20Tom%20Lesluyes%2C%20Anna%20Simeonova-Chergou%2C%20Frederik%20Wenz%2C%20Peter%20Hohenberger%2C%20Frederic%20Chibon%2C%20and%20Sophie%20Le%20Guellec.%20%26%23x201C%3BImpact%20of%20Preoperative%20Treatment%20on%20the%20CINSARC%20Prognostic%20Signature%3A%20Translational%20Research%20Results%20from%20a%26%23xA0%3BPhase%26%23xA0%3B1%20Trial%20of%20the%20German%20Interdisciplinary%20Sarcoma%20Group%20%28GISG%2003%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BStrahlentherapie%20Und%20Onkologie%3A%20Organ%20Der%20Deutschen%20Rontgengesellschaft%20...%20%5Bet%20Al%5D%26lt%3B%5C%2Fi%26gt%3B%20196%2C%20no.%203%20%28March%202020%29%3A%20280%26%23x2013%3B85.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00066-019-01543-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00066-019-01543-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20preoperative%20treatment%20on%20the%20CINSARC%20prognostic%20signature%3A%20translational%20research%20results%20from%20a%5Cu00a0phase%5Cu00a01%20trial%20of%20the%20German%20Interdisciplinary%20Sarcoma%20Group%20%28GISG%2003%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%22%2C%22lastName%22%3A%22Jakob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Simeonova-Chergou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederik%22%2C%22lastName%22%3A%22Wenz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Hohenberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20CINSARC%20%28Complexity%20INdex%20in%20SARComas%29%20is%20a%5Cu00a0prognostic%20signature%20for%20soft%20tissue%20sarcoma%20that%20determines%20the%20risk%20for%20recurrence%20and%20may%20serve%20to%20guide%20the%20decision%20for%20adjuvant%20chemotherapy.%20The%20aim%20of%20this%20study%20was%20to%20compare%20the%20CINSARC%20signature%20of%20pre-%20and%20posttreatment%20biopsies%20of%20sarcoma%20patients%20treated%20within%20a%5Cu00a0phase%5Cu00a0I%20trial%20evaluating%20preoperative%20sunitinib%20and%20irradiation.%5CnMETHODS%3A%20We%20retrieved%2014%5Cu00a0pairs%20of%20formalin-fixed%20paraffin-embedded%20blocks%20from%20pretreatment%20biopsies%20and%20posttreatment%20resection%20specimens%20and%20performed%20expression%20profiling%20of%20the%2067%5Cu00a0CINSARC%20signature%20genes.%5CnRESULTS%3A%20In%205%5C%2F14%5Cu00a0patients%2C%20both%20probes%20were%20unsuitable%20for%20expression%20analysis%20because%20there%20was%20no%20%28vital%29%20tissue%20left%20in%20biopsies%20or%20resection%20specimens.%20Comparing%20the%20CINSARC%20risk%20classification%20before%20and%20after%20treatment%20in%20the%20remaining%20patients%2C%202%5C%2F9%5Cu00a0shifted%20from%20a%5Cu00a0high-%20to%20a%5Cu00a0low-risk%20classification%20for%20metastatic%20disease%20after%20preoperative%20treatment%20with%20radiation%20therapy%20plus%20sunitinib%20and%207%5C%2F9%5Cu00a0pairs%20of%20pre-%20and%20posttreatment%20biopsies%20revealed%20identical%20results.%5CnCONCLUSION%3A%20Concurrent%20radiation%20therapy%20and%20sunitinib%20leads%20to%20diverging%20results%20of%20prognostic%20gene%20array%20testing%20in%20a%5Cu00a0relevant%20proportion%20of%20sarcoma%20patients.%20These%20changes%20may%20reflect%20tumor%20heterogeneity%2C%20local%20treatment%20effects%2C%20or%20prognostic%20changes%20of%20the%20disease.%20Caution%20is%20advised%20in%20the%20selection%20of%20samples%20and%20interpretation%20of%20test%20results.%22%2C%22date%22%3A%22Mar%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00066-019-01543-5%22%2C%22ISSN%22%3A%221439-099X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A28%3A30Z%22%7D%7D%2C%7B%22key%22%3A%222K4CKQ3I%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Salas%20and%20Chibon%22%2C%22parsedDate%22%3A%222020-01-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSalas%2C%20S%26%23xE9%3Bbastien%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BBiology%20and%20signaling%20pathways%20involved%20in%20the%20oncogenesis%20of%20desmoid%20tumors.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2016%2C%202020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2019.12.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2019.12.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Biology%20and%20signaling%20pathways%20involved%20in%20the%20oncogenesis%20of%20desmoid%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Salas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Desmoid%20tumors%20%28TDs%29%20are%20derived%20from%20mesenchymal%20stem%20cells%20and%20their%20pathogenesis%20is%20strongly%20linked%20to%20the%20Wingless%5C%2FWnt%20cascade%20where%20the%20deregulation%20of%20%5Cu03b2-catenin%20plays%20a%20major%20role.%20A%20mutation%20of%20the%20CTNNB1%20encoding%20%5Cu03b2-catenin%20is%20found%20in%20the%20majority%20of%20sporadic%20TD%20cases%20and%20constitutional%20mutations%20of%20APC%20have%20been%20described%20in%20heritable%20forms%20in%20patients%20with%20familial%20adenomatous%20polyposis%20%28FAP%29.%20Estrogens%20could%20also%20play%20a%20role%20in%20pathogenesis%20and%20this%20is%20the%20basis%20for%20the%20use%20of%20hormone%20therapy.%20Other%20signaling%20pathways%20have%20been%20involved%20in%20the%20development%20of%20TDs%20such%20as%20Notch%2C%20Hedgehog%2C%20JAK%5C%2FSTAT%2C%20PI3%20Kinase%5C%2FAKT%20and%20mTOR.%20Metalloproteases%20are%20expressed%20in%20TDs%20and%20play%20a%20role%20in%20invasiveness.%20TGF-%5Cu00df%2C%20as%20a%20growth%20factor%2C%20stimulates%20the%20transcriptional%20activity%20of%20%5Cu03b2-catenin.%20Future%20studies%20will%20need%20to%20focus%20on%20better%20describing%20and%20understanding%20the%20immune%20environment%20of%20TDs.%20One%20of%20the%20major%20difficulties%20for%20the%20experimental%20study%20of%20TDs%20is%20the%20virtual%20absence%20of%20a%20preclinical%20model%2C%20either%20in%20vitro%20or%20in%20vivo.%20This%20is%20partly%20why%20the%20interactions%20between%20the%20different%20signaling%20pathways%20presented%20here%20and%20their%20consequences%20for%20the%20development%20of%20TDs%20are%20still%20poorly%20understood.%22%2C%22date%22%3A%22Jan%2016%2C%202020%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2019.12.003%22%2C%22ISSN%22%3A%221769-6917%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A36%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22S66C8KEI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dufresne%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDufresne%2C%20A.%2C%20T.%20Lesluyes%2C%20C.%20M%26%23xE9%3Bn%26%23xE9%3Btrier-Caux%2C%20M.%20Brahmi%2C%20E.%20Darbo%2C%20M.%20Toulmonde%2C%20A.%20Italiano%2C%20et%20al.%20%26%23x201C%3BSpecific%20Immune%20Landscapes%20and%20Immune%20Checkpoint%20Expressions%20in%20Histotypes%20and%20Molecular%20Subtypes%20of%20Sarcoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncoImmunology%26lt%3B%5C%2Fi%26gt%3B%209%2C%20no.%201%20%28January%201%2C%202020%29%3A%201792036.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2020.1792036%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2020.1792036%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Specific%20immune%20landscapes%20and%20immune%20checkpoint%20expressions%20in%20histotypes%20and%20molecular%20subtypes%20of%20sarcoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22M%5Cu00e9n%5Cu00e9trier-Caux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Darbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Mir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.M.%22%2C%22lastName%22%3A%22Robin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J-M%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Caux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.Y.%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-01-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1080%5C%2F2162402X.2020.1792036%22%2C%22ISSN%22%3A%222162-402X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.tandfonline.com%5C%2Fdoi%5C%2Ffull%5C%2F10.1080%5C%2F2162402X.2020.1792036%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22THDAINSI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delespaul%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDelespaul%2C%20Lucile%2C%20Caroline%20G%26%23xE9%3Blabert%2C%20Tom%20Lesluyes%2C%20Sophie%20Le%20Guellec%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Laura%20Leroy%2C%20Jessica%20Baud%2C%20Candice%20Merle%2C%20Lydia%20Lartigue%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BCell%26%23x2013%3BCell%20Fusion%20of%20Mesenchymal%20Cells%20with%20Distinct%20Differentiations%20Triggers%20Genomic%20and%20Transcriptomic%20Remodelling%20toward%20Tumour%20Aggressiveness.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScientific%20Reports%26lt%3B%5C%2Fi%26gt%3B%2010%2C%20no.%201%20%282020%29%3A%2021634.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-78502-z%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-78502-z%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cell%5Cu2013cell%20fusion%20of%20mesenchymal%20cells%20with%20distinct%20differentiations%20triggers%20genomic%20and%20transcriptomic%20remodelling%20toward%20tumour%20aggressiveness%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22G%5Cu00e9labert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Cell%5Cu2013cell%20fusion%20is%20a%20physiological%20process%20that%20is%20hijacked%20during%20oncogenesis%20and%20promotes%20tumour%20evolution.%20The%20main%20known%20impact%20of%20cell%20fusion%20is%20to%20promote%20the%20formation%20of%20metastatic%20hybrid%20cells%20following%20fusion%20between%20mobile%20leucocytes%20and%20proliferating%20tumour%20cells.%20We%20show%20here%20that%20cell%20fusion%20between%20immortalized%20myoblasts%20and%20transformed%20fibroblasts%2C%20through%20genomic%20instability%20and%20expression%20of%20a%20specific%20transcriptomic%20profile%2C%20leads%20to%20emergence%20of%20hybrid%20cells%20acquiring%20dissemination%20properties.%20This%20is%20associated%20with%20acquisition%20of%20clonogenic%20ability%20by%20fused%20cells.%20In%20addition%2C%20by%20inheriting%20parental%20properties%2C%20hybrid%20tumours%20were%20found%20to%20mimic%20the%20histological%20characteristics%20of%20a%20specific%20histotype%20of%20sarcomas%3A%20undifferentiated%20pleomorphic%20sarcomas%20with%20incomplete%20muscular%20differentiation.%20This%20finding%20suggests%20that%20cell%20fusion%2C%20as%20macroevolution%20event%2C%20favours%20specific%20sarcoma%20development%20according%20to%20the%20differentiation%20lineage%20of%20parent%20cells.%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-020-78502-z%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-020-78502-z%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22VVJJF69F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Filleron%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFilleron%2C%20Thomas%2C%20Sophie%20Le%20Guellec%2C%20Christine%20Chevreau%2C%20Bastien%20Cabarrou%2C%20Tom%20Lesluyes%2C%20Sabrina%20Lodin%2C%20Ang%26%23xE9%3Blique%20Massoubre%2C%20et%20al.%20%26%23x201C%3BValue%20of%20Peri-Operative%20Chemotherapy%20in%20Patients%20with%20CINSARC%20High-Risk%20Localized%20Grade%201%20or%202%20Soft%20Tissue%20Sarcoma%3A%20Study%20Protocol%20of%20the%20Target%20Selection%20Phase%20III%20CHIC-STS%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2020%2C%20no.%201%20%282020%29%3A%20716.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-020-07207-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-020-07207-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Value%20of%20peri-operative%20chemotherapy%20in%20patients%20with%20CINSARC%20high-risk%20localized%20grade%201%20or%202%20soft%20tissue%20sarcoma%3A%20study%20protocol%20of%20the%20target%20selection%20phase%20III%20CHIC-STS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Lodin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e9lique%22%2C%22lastName%22%3A%22Massoubre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Poublanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-020-07207-3%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbmccancer.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs12885-020-07207-3%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22TA6SVWFL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gu%5Cu00e9rin%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGu%26%23xE9%3Brin%2C%20Amandine%2C%20Delphine%20Martire%2C%20Eva%20Trenquier%2C%20Tom%20Lesluyes%2C%20S%26%23xE9%3Bbastien%20Sagnol%2C%20Marine%20Pratlong%2C%20Elise%20Lefebvre%2C%20Fr%26%23xE9%3Bderic%20Chibon%2C%20Pascal%20Santa%20Barbara%2C%20and%20Sandrine%20Faure.%20%26%23x201C%3BLIX1%20Regulates%20YAP%20Activity%20and%20Controls%20Gastrointestinal%20Cancer%20Cell%20Plasticity.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Cellular%20and%20Molecular%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2024%2C%20no.%2016%20%282020%29%3A%209244%26%23x2013%3B54.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjcmm.15569%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjcmm.15569%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LIX1%20regulates%20YAP%20activity%20and%20controls%20gastrointestinal%20cancer%20cell%20plasticity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amandine%22%2C%22lastName%22%3A%22Gu%5Cu00e9rin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Martire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Trenquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Sagnol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Pratlong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Santa%20Barbara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Faure%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2208%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fjcmm.15569%22%2C%22ISSN%22%3A%221582-1838%2C%201582-4934%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fjcmm.15569%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22B8534R9G%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Croce%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCroce%2C%20Sabrina%2C%20Tom%20Lesluyes%2C%20Carine%20Valle%2C%20Loubna%20M%26%23x2019%3BHamdi%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Eberhard%20Stoeckle%2C%20et%20al.%20%26%23x201C%3BThe%20Nanocind%20Signature%20Is%20an%20Independent%20Prognosticator%20of%20Recurrence%20and%20Death%20in%20Uterine%20Leiomyosarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Cancer%20Research%3A%20An%20Official%20Journal%20of%20the%20American%20Association%20for%20Cancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2026%2C%20no.%204%20%2815%202020%29%3A%20855%26%23x2013%3B61.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-19-2891%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-19-2891%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Nanocind%20Signature%20Is%20an%20Independent%20Prognosticator%20of%20Recurrence%20and%20Death%20in%20Uterine%20Leiomyosarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Croce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loubna%22%2C%22lastName%22%3A%22M%27Hamdi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eberhard%22%2C%22lastName%22%3A%22Stoeckle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22No%5Cu00ebl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Quitterie%22%2C%22lastName%22%3A%22Fontanges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mojgan%22%2C%22lastName%22%3A%22Devouassoux-Shisheboran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Floquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Chakiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Mayeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flora%22%2C%22lastName%22%3A%22Rebier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00ebtan%20Marie%22%2C%22lastName%22%3A%22MacGrogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Uterine%20leiomyosarcoma%2C%20which%20accounts%20for%207%25%20of%20all%20soft-tissue%20sarcomas%20and%201%25-3%25%20of%20all%20uterine%20malignancies%2C%20is%20an%20aggressive%20tumor%20responsible%20for%20a%20significant%20proportion%20of%20uterine%20cancer-related%20deaths.%20While%20Federation%20Internationale%20des%20Gynaecologistes%20et%20Obstetristes%20%28FIGO%29%20stage%20is%20the%20most%20important%20prognostic%20factor%2C%20metastatic%20and%20relapse%20rates%20at%20stage%20I%20exceed%2050%25%20so%20it%20is%20currently%20impossible%20to%20predict%20the%20clinical%20outcome%20of%20stage%20I%20leiomyosarcomas.%20In%202010%2C%20our%20team%20published%20a%20transcriptomic%20signature%20composed%20of%2067%20genes%20related%20to%20chromosome%20biogenesis%2C%20mitosis%20control%2C%20and%20chromosome%20segregation.%20It%20has%20demonstrated%20its%20prognostic%20value%20in%20many%20cancer%20types%20and%20was%20recently%20successfully%20applied%20to%20formalin-fixed%2C%20paraffin-embedded%20sarcomas%20by%20NanoCind%20on%20NanoString%20technology%2C%20making%20another%20step%20forward%20toward%20its%20use%20in%20routine%20practice.%5CnEXPERIMENTAL%20DESIGN%3A%20Sixty%20uterine%20leiomyosarcomas%20at%20any%20stage%2C%20including%2040%20localized%20in%20the%20uterus%20%28stage%20I%29%2C%20were%20analyzed%20with%20the%20NanoCind%20%28CINSARC%20with%20NanoString%29%20signature.%20Its%20prognostic%20value%20was%20evaluated%20for%20overall%20survival%20and%20relapse-free%20survival%20and%20compared%20in%20multivariate%20analysis%20with%20other%20prognostic%20markers%20like%20FIGO%20staging%20and%20genomic%20index.%5CnRESULTS%3A%20The%20NanoCind%20signature%20was%20able%20to%20split%20the%20heterogeneous%20group%20of%20uterine%20leiomyosarcomas%20of%20any%20stage%20including%20stage%20I%20into%20two%20distinct%20groups%20with%20different%20relapse-free%20survival%20and%20overall%20survival.%20These%20results%20were%20validated%20on%20an%20independent%20cohort%20of%20uterine%20leiomyosarcomas%20in%20The%20Cancer%20Genome%20Atlas%20consortium.%5CnCONCLUSIONS%3A%20The%20NanoCind%20signature%20is%20a%20powerful%20prognosticator%20that%20outperforms%20FIGO%20staging%20and%20the%20genomic%20index.%20The%20CINSARC%20signature%20is%20platform%20independent%20and%20%26quot%3Bready%20to%20use%26quot%3B%20and%20should%20now%20be%20used%20for%20randomization%20in%20future%20therapeutic%20trials.%22%2C%22date%22%3A%2202%2015%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-19-2891%22%2C%22ISSN%22%3A%221078-0432%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A26%3A19Z%22%7D%7D%5D%7D
Croce, Sabrina, and Frédéric Chibon. “Molecular Prognostication of Uterine Smooth Muscle Neoplasms: From CGH Array to CINSARC Signature and Beyond.” Genes, Chromosomes and Cancer, November 11, 2020, gcc.22906. https://doi.org/10.1002/gcc.22906.
Lesluyes, Tom, and Frédéric Chibon. “A Global and Integrated Analysis of CINSARC-Associated Genetic Defects.” Cancer Research, October 6, 2020, canres.0512.2020. https://doi.org/10.1158/0008-5472.CAN-20-0512.
Cissé, Madi Y., Samuel Pyrdziak, Nelly Firmin, Laurie Gayte, Maud Heuillet, Floriant Bellvert, Maryse Fuentes, et al. “Targeting MDM2-Dependent Serine Metabolism as a Therapeutic Strategy for Liposarcoma.” Science Translational Medicine 12, no. 547 (June 10, 2020): eaay2163. https://doi.org/10.1126/scitranslmed.aay2163.
Merle, Candice, Noémie Thébault, Sophie LeGuellec, Jessica Baud, Gaëlle Pérot, Tom Lesluyes, Lucile Delespaul, Lydia Lartigue, and Frédéric Chibon. “Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion.” Cancers 12, no. 5 (May 19, 2020): 1281. https://doi.org/10.3390/cancers12051281.
Lartigue, Lydia, Candice Merle, Pauline Lagarde, Lucile Delespaul, Tom Lesluyes, Sophie Le Guellec, Gaelle Pérot, Laura Leroy, Jean-Michel Coindre, and Frédéric Chibon. “Genome Remodeling upon Mesenchymal Tumor Cell Fusion Contributes to Tumor Progression and Metastatic Spread.” Oncogene 39, no. 21 (May 2020): 4198–4211. https://doi.org/10.1038/s41388-020-1276-6.
Mattei, Jean Camille, Corinne Bouvier-Labit, Doriane Barets, Nicolas Macagno, Mathieu Chocry, Frédéric Chibon, Philippe Morando, et al. “Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile.” Cancers 12, no. 3 (March 3, 2020). https://doi.org/10.3390/cancers12030583.
Jakob, Jens, Tom Lesluyes, Anna Simeonova-Chergou, Frederik Wenz, Peter Hohenberger, Frederic Chibon, and Sophie Le Guellec. “Impact of Preoperative Treatment on the CINSARC Prognostic Signature: Translational Research Results from a Phase 1 Trial of the German Interdisciplinary Sarcoma Group (GISG 03).” Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft ... [et Al] 196, no. 3 (March 2020): 280–85. https://doi.org/10.1007/s00066-019-01543-5.
Salas, Sébastien, and Frédéric Chibon. “Biology and signaling pathways involved in the oncogenesis of desmoid tumors.” Bulletin Du Cancer, January 16, 2020. https://doi.org/10.1016/j.bulcan.2019.12.003.
Dufresne, A., T. Lesluyes, C. Ménétrier-Caux, M. Brahmi, E. Darbo, M. Toulmonde, A. Italiano, et al. “Specific Immune Landscapes and Immune Checkpoint Expressions in Histotypes and Molecular Subtypes of Sarcoma.” OncoImmunology 9, no. 1 (January 1, 2020): 1792036. https://doi.org/10.1080/2162402X.2020.1792036.
Delespaul, Lucile, Caroline Gélabert, Tom Lesluyes, Sophie Le Guellec, Gaëlle Pérot, Laura Leroy, Jessica Baud, Candice Merle, Lydia Lartigue, and Frédéric Chibon. “Cell–Cell Fusion of Mesenchymal Cells with Distinct Differentiations Triggers Genomic and Transcriptomic Remodelling toward Tumour Aggressiveness.” Scientific Reports 10, no. 1 (2020): 21634. https://doi.org/10.1038/s41598-020-78502-z.
Filleron, Thomas, Sophie Le Guellec, Christine Chevreau, Bastien Cabarrou, Tom Lesluyes, Sabrina Lodin, Angélique Massoubre, et al. “Value of Peri-Operative Chemotherapy in Patients with CINSARC High-Risk Localized Grade 1 or 2 Soft Tissue Sarcoma: Study Protocol of the Target Selection Phase III CHIC-STS Trial.” BMC Cancer 20, no. 1 (2020): 716. https://doi.org/10.1186/s12885-020-07207-3.
Guérin, Amandine, Delphine Martire, Eva Trenquier, Tom Lesluyes, Sébastien Sagnol, Marine Pratlong, Elise Lefebvre, Fréderic Chibon, Pascal Santa Barbara, and Sandrine Faure. “LIX1 Regulates YAP Activity and Controls Gastrointestinal Cancer Cell Plasticity.” Journal of Cellular and Molecular Medicine 24, no. 16 (2020): 9244–54. https://doi.org/10.1111/jcmm.15569.
Croce, Sabrina, Tom Lesluyes, Carine Valle, Loubna M’Hamdi, Noémie Thébault, Gaëlle Pérot, Eberhard Stoeckle, et al. “The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 26, no. 4 (15 2020): 855–61. https://doi.org/10.1158/1078-0432.CCR-19-2891.
PUBLICATIONS 2019
7813506
CF9MRXB4
2019
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22A4LLPCUM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delespaul%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDelespaul%2C%20Lucile%2C%20Candice%20Merle%2C%20Tom%20Lesluyes%2C%20Pauline%20Lagarde%2C%20Sophie%20Le%20Guellec%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Jessica%20Baud%2C%20et%20al.%20%26%23x201C%3BFusion-Mediated%20Chromosomal%20Instability%20Promotes%20Aneuploidy%20Patterns%20That%20Resemble%20Human%20Tumors.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncogene%26lt%3B%5C%2Fi%26gt%3B%2C%20July%203%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-019-0859-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-019-0859-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fusion-mediated%20chromosomal%20instability%20promotes%20aneuploidy%20patterns%20that%20resemble%20human%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%22%2C%22lastName%22%3A%22Carlotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coralie%22%2C%22lastName%22%3A%22Danet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murielle%22%2C%22lastName%22%3A%22F%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Durrieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Teichmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Oncogenesis%20is%20considered%20to%20result%20from%20chromosomal%20instability%2C%20in%20addition%20to%20oncogene%20and%20tumor-suppressor%20alterations.%20Intermediate%20to%20aneuploidy%20and%20chromosomal%20instability%2C%20genome%20doubling%20is%20a%20frequent%20event%20in%20tumor%20development%20but%20the%20mechanisms%20driving%20tetraploidization%20and%20its%20impact%20remain%20unexplored.%20Cell%20fusion%2C%20one%20of%20the%20pathways%20to%20tetraploidy%2C%20is%20a%20physiological%20process%20involved%20in%20mesenchymal%20cell%20differentiation.%20Besides%20simple%20genome%20doubling%2C%20cell%20fusion%20results%20in%20the%20merging%20of%20two%20different%20genomes%20that%20can%20be%20destabilized%20upon%20proliferation.%20By%20testing%20whether%20cell%20fusion%20is%20involved%20in%20mesenchymal%20oncogenesis%2C%20we%20provide%20evidence%20that%20it%20induces%20genomic%20instability%20and%20mediates%20tumor%20initiation.%20After%20a%20latency%20period%2C%20the%20tumor%20emerges%20with%20the%20cells%20most%20suited%20for%20its%20development.%20Furthermore%2C%20hybrid%20tumor%20genomes%20were%20stabilized%20after%20this%20selection%20process%20and%20were%20very%20close%20to%20those%20of%20human%20pleomorphic%20mesenchymal%20tumors.%20Thus%20genome%20restructuring%20triggered%20by%20cell%20fusion%20may%20account%20for%20the%20chromosomal%20instability%20involved%20in%20oncogenesis.%22%2C%22date%22%3A%22Jul%2003%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41388-019-0859-6%22%2C%22ISSN%22%3A%221476-5594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22JRZG7GIG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mauduit%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMauduit%2C%20Olivier%2C%20Vanessa%20Delcroix%2C%20Tom%20Lesluyes%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Pauline%20Lagarde%2C%20Lydia%20Lartigue%2C%20Jean-Yves%20Blay%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BRecurrent%20DMD%20Deletions%20Highlight%20Specific%20Role%20of%20Dp71%20Isoform%20in%20Soft-Tissue%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%207%20%28July%201%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11070922%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11070922%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Recurrent%20DMD%20Deletions%20Highlight%20Specific%20Role%20of%20Dp71%20Isoform%20in%20Soft-Tissue%20Sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Mauduit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Delcroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Soft-tissue%20sarcomas%20%28STS%29%20are%20rare%20tumors%20whose%20oncogenesis%20remains%20unknown%20and%20for%20which%20no%20common%20therapeutic%20target%20has%20yet%20been%20identified.%20Analysis%20of%20318%20STS%20by%20CGH%20array%20evidenced%20a%20frequent%20deletion%20affecting%20the%20DMD%20gene%20%28encoding%20dystrophin%20isoforms%29%20in%2016.5%25%20of%20STS%2C%20including%20sarcomas%20with%20complex%20genomics%2C%20gastrointestinal%20tumors%20%28GIST%29%2C%20and%20synovial%20sarcomas%20%28SS%29.%20These%20deletions%20are%20significantly%20associated%20with%20metastatic%20progression%2C%20thus%20suggesting%20the%20role%20of%20DMD%20downregulation%20in%20the%20acquisition%20of%20aggressive%20phenotypes.%20We%20observed%20that%20targeted%20deletions%20of%20DMD%20were%20restricted%20to%20the%205%26%23039%3B%20region%20of%20the%20gene%2C%20which%20is%20responsible%20for%20the%20transcription%20of%20Dp427.%20Analysis%20of%20STS%20tumors%20and%20cell%20lines%20by%20RNA%20sequencing%20revealed%20that%20only%20the%20Dp71%20isoform%20was%20widely%20expressed.%20Dp427%20depletion%20had%20no%20effect%20on%20cell%20growth%20or%20migration.%20However%2C%20Dp71%20inhibition%20by%20shRNA%20dramatically%20reduced%20the%20cell%20proliferation%20and%20clonogenicity%20of%20three%20STS%20cell%20lines%2C%20likely%20by%20altering%20the%20cell%20cycle%20progression%20through%20the%20G2%5C%2FM-phase.%20Our%20work%20demonstrates%20that%20DMD%20deletions%20are%20not%20restricted%20to%20myogenic%20tumors%20and%20could%20be%20used%20as%20a%20biomarker%20for%20metastatic%20evolution%20in%20STS.%20Dp71%20seems%20to%20play%20an%20essential%20role%20in%20tumor%20growth%2C%20thus%20providing%20a%20potential%20target%20for%20future%20STS%20treatments.%22%2C%22date%22%3A%22Jul%2001%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers11070922%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A24Z%22%7D%7D%2C%7B%22key%22%3A%2264AD9ZGM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesluyes%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLesluyes%2C%20Tom%2C%20Jessica%20Baud%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20C%26%23xE9%3Bline%20Charon-Barra%2C%20Axel%20You%2C%20Isabelle%20Valo%2C%20C%26%23xE9%3Bline%20Bazille%2C%20et%20al.%20%26%23x201C%3BGenomic%20and%20Transcriptomic%20Comparison%20of%20Post-Radiation%20versus%20Sporadic%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BModern%20Pathology%3A%20An%20Official%20Journal%20of%20the%20United%20States%20and%20Canadian%20Academy%20of%20Pathology%2C%20Inc%26lt%3B%5C%2Fi%26gt%3B%2C%20June%2026%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0300-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0300-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Genomic%20and%20transcriptomic%20comparison%20of%20post-radiation%20versus%20sporadic%20sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Charon-Barra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22You%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Valo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Bazille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Mishellany%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Leroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Renard-Oldrini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Terrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marick%22%2C%22lastName%22%3A%22La%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Neuville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Collin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Maingon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Post-radiation%20sarcomas%20are%20rare%20secondary%20cancers%20arising%20from%20radiation%20therapies.%20To%20date%2C%20few%20genetic%20specificities%20have%20been%20described%20for%20such%20malignancies%20and%20the%20oncogenesis%20of%20sarcomas%20with%20complex%20genetics%20%28both%20sporadic%20and%20post-radiation%29%20remains%20largely%20misunderstood.%20We%20performed%20genomic%20and%20transcriptomic%20analyses%20on%2077%20post-radiation%20sarcomas%20using%20DNA-array%20and%20RNA%20sequencing.%20Consequently%2C%20we%20were%20able%20to%20investigate%20changes%20in%20copy%20number%20variations%2C%20transcriptome%20profiling%2C%20fusion%20gene%20expression%2C%20and%20mutational%20landscapes.%20We%20compare%20these%20data%20to%20a%20reference%20cohort%20of%2093%20sporadic%20sarcomas.%20At%20genomic%20level%2C%20similar%20chromosomal%20complexity%20was%20observed%20both%20in%20post-radiation%20and%20sporadic%20sarcomas%20with%20complex%20genetics.%20We%20found%20more%20frequent%20CDKN2A%20and%20CDKN2B%20%28coding%20for%20p14%5C%2Fp16%20and%20p15%20proteins%2C%20respectively%3B%20at%209p21.3%29%20losses%20in%20post-radiation%20%2871%25%29%20than%20in%20sporadic%20tumors%20%2839%25%3B%20P%5Cu2009%3D%5Cu20096.92e-3%29.%20Among%20all%20detected%20fusion%20genes%20and%20punctual%20variations%2C%20few%20specificities%20were%20observed%20between%20these%20groups%20and%20such%20alterations%20are%20not%20able%20to%20drive%20a%20strong%20and%20specific%20oncogenesis.%20Recurrent%20MYC%20amplifications%20%2896%25%29%20and%20KDR%20variants%20%288%25%29%20were%20detected%20in%20post-radiation%20angiosarcomas%2C%20in%20agreement%20with%20the%20literature.%20Transcriptomic%20analysis%20of%20such%20angiosarcomas%20revealed%20two%20distinct%20groups%20harboring%20different%20genomic%20imbalances%20%28in%20particular%20gains%20of%2017q24.2-17qter%29%20with%20different%20clinical%20courses%20according%20to%20patient%26%23039%3Bs%20vital%20status.%20Differential%20gene%20expression%20analysis%20permitted%20to%20focus%20on%20the%20immune%20response%20as%20a%20potential%20actor%20to%20tumor%20aggressiveness.%20Histochemistry%20validated%20a%20lower%20inflammation%20and%20lower%20immune%20infiltrate%20at%20tumor%20periphery%20for%20highly%20aggressive%20angiosarcomas.%20Our%20results%20provide%20new%20genomic%20and%20transcriptomic%20information%20about%20post-radiation%20sarcomas.%20The%20techniques%20we%20used%20%28RNA-seq%20and%20DNA-arrays%29%20did%20not%20highlight%20major%20differences%20in%20sarcomas%20with%20complex%20genetics%20depending%20on%20the%20radiation%20context%2C%20revealing%20similar%20patterns%20of%20transcriptomic%20profiles%20and%20chromosomal%20copy%20number%20variations.%20Additional%20characterizations%2C%20particularly%20whole%20genome%20sequencing%2C%20could%20measure%20changes%20in%20DNA%20following%20radiation%20therapy%20in%20such%20malignancies%20and%20may%20precise%20their%20oncogenesis.%22%2C%22date%22%3A%22Jun%2026%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41379-019-0300-2%22%2C%22ISSN%22%3A%221530-0285%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22DM9486JU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chibon%20et%20al.%22%2C%22parsedDate%22%3A%222019-04-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChibon%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%2C%20Elodie%20Darbo%2C%20and%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot.%20%26%23x201C%3BLeiomyosarcomas%3A%20Whole%20Genome%20Sequencing%20for%20a%20Whole%20Biology%20Characterization.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCurrent%20Opinion%20in%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20April%2024%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCCO.0000000000000550%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCCO.0000000000000550%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Leiomyosarcomas%3A%20whole%20genome%20sequencing%20for%20a%20whole%20biology%20characterization%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Darbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%20OF%20REVIEW%3A%20Leiomyosarcoma%20%28LMS%29%20is%20among%20the%20more%20aggressive%20sarcomas%20and%20still%20suffers%20from%20the%20lack%20of%20efficient%20systemic%20treatment%20after%2C%20or%20before%2C%20surgery.%20During%20the%20last%20decades%2C%20one%20provider%20of%20therapeutic%20improvement%20has%20been%20the%20targeting%20of%20genome%20alterations.%20Efforts%20have%20thus%20been%20done%20to%20apply%20next-generation%20sequencing%20approaches%20to%20those%20tumours%20to%20decipher%20their%20oncogenesis%20and%20find%20out%20such%20targets.%5CnRECENT%20FINDINGS%3A%20Sequencing%20performed%20so%20far%2C%20based%20on%20exome%2C%20mostly%20confirmed%20that%20p53%20and%20RB1%20are%20the%20two%20main%20pathways%20altered%20in%20LMS%20oncogenesis.%20There%20are%20few%20point%20mutations%20in%20LMS%20genome%2C%20which%20is%20mainly%20characterized%20by%20numerous%20chromosomal%20rearrangements.%20Data%20from%20whole%20genome%20sequencing%20are%20now%20mandatory%20to%20decipher%20mechanisms%20triggering%20chromosomal%20instability%20and%20mutational%20process.%5CnSUMMARY%3A%20Although%20each%20LMS%20appears%20to%20have%20quite%20private%20genetic%20alterations%20leading%20to%20oncogenesis%2C%20it%20is%20likely%20that%20the%20altered%20biological%20pathways%20are%20relatively%20homogeneous%20within%20each%20of%20the%20LMS%20subgroups.%20Understanding%20this%20oncogenesis%2C%20thanks%20to%20integrated%20approaches%20involving%20whole%20genome%20and%20transcriptome%20sequencing%20together%20with%20functional%20and%20clinical%20characterizations%20will%20certainly%20give%20us%20the%20keys%20to%20relevant%20and%20effective%20new%20therapeutic%20approaches.%22%2C%22date%22%3A%22Apr%2024%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FCCO.0000000000000550%22%2C%22ISSN%22%3A%221531-703X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A14Z%22%7D%7D%2C%7B%22key%22%3A%224IRDFZL5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Loarer%20et%20al.%22%2C%22parsedDate%22%3A%222019-03-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLe%20Loarer%2C%20Fran%26%23xE7%3Bois%2C%20Sophie%20Laffont%2C%20Tom%20Lesluyes%2C%20Franck%20Tirode%2C%20Cristina%20Antonescu%2C%20Anne-Catherine%20Baglin%2C%20Lucile%20Delespaul%2C%20et%20al.%20%26%23x201C%3BClinicopathologic%20and%20Molecular%20Features%20of%20a%20Series%20of%2041%20Biphenotypic%20Sinonasal%20Sarcomas%20Expanding%20Their%20Molecular%20Spectrum.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20American%20Journal%20of%20Surgical%20Pathology%26lt%3B%5C%2Fi%26gt%3B%2C%20March%201%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001238%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001238%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinicopathologic%20and%20Molecular%20Features%20of%20a%20Series%20of%2041%20Biphenotypic%20Sinonasal%20Sarcomas%20Expanding%20Their%20Molecular%20Spectrum%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Laffont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Tirode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Antonescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Catherine%22%2C%22lastName%22%3A%22Baglin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Hostein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Costes-Martineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Castain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Eimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Le%20Bail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Wassef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%5D%2C%22abstractNote%22%3A%22Biphenotypic%20sinonasal%20sarcoma%20%28BSNS%29%20is%20a%20locally%20aggressive%20tumor%20occurring%20in%20the%20sinonasal%20region.%20It%20harbors%20both%20myogenic%20and%20neural%20differentiation%20and%20is%20characterized%20by%20PAX3%20rearrangement%20with%20MAML3%20as%20the%20most%20frequent%20fusion%20partner%2C%20but%20the%20partner%20of%20PAX3%20remains%20unidentified%20in%20a%20subset%20of%20cases.%20About%2070%20cases%20have%20been%20reported%20so%20far.%20In%20this%20study%2C%20we%20report%20a%20series%20of%2041%20cases%20with%20clinical%2C%20pathologic%2C%20and%20molecular%20description.%20Twenty-five%20%2861%25%29%20patients%20were%20female%20individuals%2C%20and%20the%20median%20age%20was%2049%20years.%20Tumors%20arose%20predominantly%20in%20the%20nasal%20cavity%20and%20ethmoidal%20sinuses.%20Local%20recurrences%20occurred%20in%208%20cases%20of%20the%2025%20%2832%25%29.%20Histologic%20features%20were%20characteristic%20of%20BSNS%2C%20with%205%20cases%20showing%20focal%20rhabdomyoblastic%20differentiation.%20Immunohistochemistry%20showed%20a%20constant%20positivity%20of%20S100%20protein%20and%20PAX3%20and%20negativity%20of%20SOX10.%20MyoD1%20was%20focally%20positive%20in%2091%25%20of%20cases%2C%20whereas%20only%2020%25%20were%20positive%20for%20myogenin.%20Molecular%20analysis%20showed%20a%20PAX3-MAML3%20transcript%20in%2037%20cases%20%2890%25%29.%20RNA%20sequencing%20was%20performed%20in%20the%204%20negative%20cases%20for%20PAX3-MAML3%20fusion%2C%20and%20it%20showed%20that%201%20case%20harbored%20a%20PAX3-FOXO1%20fusion%2C%20as%20previously%20described%20in%20the%20literature%2C%20and%202%20novel%20fusions%3A%20PAX3-WWTR1%20fusion%20in%202%20cases%20and%20PAX3-NCOA2%20fusion%20in%201%20case.%20RNA%20sequencing%20results%20were%20confirmed%20by%20fluorescence%20in%20situ%20hybridization%2C%20reverse%20transcription-polymerase%20chain%20reaction%2C%20and%20Sanger%20sequencing.%20The%20PAX3-NCOA2-positive%20case%20showed%20focal%20rhabdomyoblastic%20differentiation.%20In%20conclusion%2C%20we%20report%202%20novel%20fusions%20%28PAX3-WWTR1%20and%20PAX3-NCOA2%29%20in%20BSNS%20and%20show%20that%20MyoD1%20is%20more%20sensitive%20than%20myogenin%20for%20demonstrating%20myogenic%20differentiation%20in%20this%20tumor.%22%2C%22date%22%3A%22Mar%2001%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FPAS.0000000000001238%22%2C%22ISSN%22%3A%221532-0979%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A04Z%22%7D%7D%2C%7B%22key%22%3A%222USM3MYE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vitiello%20et%20al.%22%2C%22parsedDate%22%3A%222019-02-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVitiello%2C%20Gerardo%20A.%2C%20Timothy%20G.%20Bowler%2C%20Mengyuan%20Liu%2C%20Benjamin%20D.%20Medina%2C%20Jennifer%20Q.%20Zhang%2C%20Nesteene%20J.%20Param%2C%20Jennifer%20K.%20Loo%2C%20et%20al.%20%26%23x201C%3BDifferential%20Immune%20Profiles%20Distinguish%20the%20Mutational%20Subtypes%20of%20Gastrointestinal%20Stromal%20Tumor.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20Clinical%20Investigation%26lt%3B%5C%2Fi%26gt%3B%2C%20February%2014%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI124108%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI124108%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Differential%20immune%20profiles%20distinguish%20the%20mutational%20subtypes%20of%20gastrointestinal%20stromal%20tumor%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerardo%20A.%22%2C%22lastName%22%3A%22Vitiello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20G.%22%2C%22lastName%22%3A%22Bowler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mengyuan%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20D.%22%2C%22lastName%22%3A%22Medina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20Q.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nesteene%20J.%22%2C%22lastName%22%3A%22Param%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20K.%22%2C%22lastName%22%3A%22Loo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20L.%22%2C%22lastName%22%3A%22Goldfeder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferdinand%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shan%22%2C%22lastName%22%3A%22Zeng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20P.%22%2C%22lastName%22%3A%22DeMatteo%22%7D%5D%2C%22abstractNote%22%3A%22Gastrointestinal%20stromal%20tumor%20%28GIST%29%20is%20the%20most%20common%20human%20sarcoma%2C%20frequently%20characterized%20by%20an%20oncogenic%20mutation%20in%20the%20KIT%20or%20platelet-derived%20growth%20factor%20receptor%20alpha%20%28PDGFRA%29%20genes.%20We%20performed%20RNA%20sequencing%20of%2075%20human%20GIST%20tumors%20from%2075%20patients%2C%20comprising%20the%20largest%20cohort%20of%20GISTs%20sequenced%20to%20date%2C%20in%20order%20to%20discover%20differences%20in%20the%20immune%20infiltrates%20of%20KIT%20and%20PDGFRA-mutant%20GIST.%20Through%20bioinformatics%2C%20immunohistochemistry%2C%20and%20flow%20cytometry%2C%20we%20found%20that%20PDGFRA-mutant%20GISTs%20harbored%20more%20immune%20cells%20with%20increased%20cytolytic%20activity%20when%20compared%20to%20KIT-mutant%20GISTs.%20PDGFRA-mutant%20GISTs%20expressed%20many%20chemokines%2C%20such%20as%20CXCL14%2C%20at%20a%20significantly%20higher%20level%20when%20compared%20to%20KIT-mutant%20GISTs%20and%20exhibited%20more%20diverse%20driver-derived%20neoepitope%3AHLA%20binding%2C%20both%20of%20which%20may%20contribute%20to%20PDGFRA-mutant%20GIST%20immunogenicity.%20Through%20machine%20learning%2C%20we%20generated%20gene%20expression-based%20immune%20profiles%20capable%20of%20differentiating%20KIT%20and%20PDGFRA-mutant%20GISTs%2C%20and%20also%20identified%20additional%20immune%20features%20of%20high%20PD-1%20and%20PD-L1%20expressing%20tumors%20across%20all%20GIST%20mutational%20subtypes%2C%20which%20may%20provide%20insight%20into%20immunotherapeutic%20opportunities%20and%20limitations%20in%20GIST.%22%2C%22date%22%3A%22Feb%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1172%5C%2FJCI124108%22%2C%22ISSN%22%3A%221558-8238%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22TVXWM6WZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mauduit%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMauduit%2C%20Olivier%2C%20C%26%23xE9%3Bline%20Brulard%2C%20Tom%20Lesluyes%2C%20Vanessa%20Delcroix%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Nina%20Choublier%2C%20Mickael%20Michaud%2C%20et%20al.%20%26%23x201C%3BRCBTB1%20Deletion%20Is%20Associated%20with%20Metastatic%20Outcome%20and%20Contributes%20to%20Docetaxel%20Resistance%20in%20Nontranslocation-Related%20Pleomorphic%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%201%20%28January%2011%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11010081%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11010081%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22RCBTB1%20Deletion%20Is%20Associated%20with%20Metastatic%20Outcome%20and%20Contributes%20to%20Docetaxel%20Resistance%20in%20Nontranslocation-Related%20Pleomorphic%20Sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Mauduit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Brulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Delcroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%22%2C%22lastName%22%3A%22Choublier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Michaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Aurias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Half%20of%20soft-tissue%20sarcomas%20are%20tumors%20with%20complex%20genomics%2C%20which%20display%20no%20specific%20genetic%20alterations%20and%20respond%20poorly%20to%20treatment.%20It%20is%20therefore%20necessary%20to%20find%20new%20therapeutic%20targets%20for%20these%20sarcomas.%20Despite%20genetic%20heterogeneity%20across%20samples%2C%20oncogenesis%20may%20be%20driven%20by%20common%20pathway%20alterations.%20Therefore%2C%20genomic%20and%20transcriptomic%20profiles%20of%20106%20sarcomas%20with%20complex%20genomics%20were%20analyzed%20to%20identify%20common%20pathways%20with%20altered%20genes.%20This%20brought%20out%20a%20gene%20belonging%20to%20the%20%26quot%3Bcell%20cycle%26quot%3B%20biological%20pathway%2C%20RCBTB1%20%28RCC1%20And%20BTB%20Domain%20Containing%20Protein%201%29%2C%20which%20is%20lost%20and%20downregulated%20in%2062.5%25%20of%20metastatic%20tumors%20against%2034%25%20of%20non-metastatic%20tumors.%20A%20retrospective%20study%20of%20three%20sarcoma%20cohorts%20revealed%20that%20low%20RCBTB1%20expression%20is%20prognostic%20for%20metastatic%20progression%2C%20specifically%20in%20patients%20that%20received%20chemotherapy.%20In%20vitro%20and%20in%20vivo%2C%20RCBTB1%20overexpression%20in%20leiomyosarcoma%20cells%20specifically%20sensitized%20to%20docetaxel-induced%20apoptosis.%20This%20was%20associated%20with%20increased%20mitotic%20rate%20in%20vitro%20and%20higher%20growth%20rate%20of%20xenografts.%20By%20contrast%2C%20RCBTB1%20inhibition%20decreased%20cell%20proliferation%20and%20protected%20sarcoma%20cells%20from%20apoptosis%20induced%20by%20docetaxel.%20Collectively%2C%20these%20data%20evidenced%20that%20RCBTB1%20is%20frequently%20deleted%20in%20sarcomas%20with%20complex%20genomics%20and%20that%20its%20downregulation%20is%20associated%20with%20a%20higher%20risk%20of%20developing%20metastasis%20for%20patients%20receiving%20chemotherapy%2C%20likely%20due%20to%20their%20higher%20resistance%20to%20docetaxel.%22%2C%22date%22%3A%22Jan%2011%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers11010081%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A22%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22TIS82J4D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valentin%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BValentin%2C%20T.%2C%20T.%20Lesluyes%2C%20S.%20Le%20Guellec%2C%20and%20F.%20Chibon.%20%26%23x201C%3BChemotherapy%20in%20Localized%20Soft%20Tissue%20Sarcoma%3A%20Will%20We%20Soon%20Have%20to%20Treat%20Grade%201%20Tumors%3F%20Update%20on%20CINSARC%20Performances.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2030%2C%20no.%201%20%28January%201%2C%202019%29%3A%20153%26%23x2013%3B55.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fannonc%5C%2Fmdy465%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fannonc%5C%2Fmdy465%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Chemotherapy%20in%20localized%20soft%20tissue%20sarcoma%3A%20will%20we%20soon%20have%20to%20treat%20grade%201%20tumors%3F%20Update%20on%20CINSARC%20performances%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jan%2001%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fannonc%5C%2Fmdy465%22%2C%22ISSN%22%3A%221569-8041%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A36%3A21Z%22%7D%7D%2C%7B%22key%22%3A%2237NR77WY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Timbergen%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTimbergen%2C%20Milea%20J.%20M.%2C%20Matthijs%20L.%20Janssen%2C%20Cornelis%20Verhoef%2C%20Dirk%20J.%20Gr%26%23xFC%3Bnhagen%2C%20Frederic%20Chibon%2C%20Marcel%20Smid%2C%20Stefan%20Sleijfer%2C%20and%20Erik%20A.%20C.%20Wiemer.%20%26%23x201C%3BWnt%20Targets%20Genes%20Are%20Not%20Differentially%20Expressed%20in%20Desmoid%20Tumors%20Bearing%20Different%20Activating%20%26%23x3B2%3B-Catenin%20Mutations.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Surgical%20Oncology%3A%20The%20Journal%20of%20the%20European%20Society%20of%20Surgical%20Oncology%20and%20the%20British%20Association%20of%20Surgical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2045%2C%20no.%204%20%282019%29%3A%20691%26%23x2013%3B98.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2018.09.019%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2018.09.019%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Wnt%20targets%20genes%20are%20not%20differentially%20expressed%20in%20desmoid%20tumors%20bearing%20different%20activating%20%5Cu03b2-catenin%20mutations%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milea%20J.%20M.%22%2C%22lastName%22%3A%22Timbergen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthijs%20L.%22%2C%22lastName%22%3A%22Janssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornelis%22%2C%22lastName%22%3A%22Verhoef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%20J.%22%2C%22lastName%22%3A%22Gr%5Cu00fcnhagen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Smid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Sleijfer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20A.%20C.%22%2C%22lastName%22%3A%22Wiemer%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Sporadic%20desmoid-type%20fibromatosis%20%28DTF%29%20is%20a%20rare%20soft%20tissue%20tumor%20of%20mesenchymal%20origin.%20It%20is%20characterized%20by%20local%20invasive%20growth%20and%20unpredictable%20growth%20behavior.%20Three%20distinct%20mutations%20involving%20the%20CTNNB1%20%28%5Cu03b2-catenin%29%20gene%20have%20been%20identified%20in%20the%20vast%20majority%20of%20DTF%20tumors%2C%20which%20cause%20activation%20of%20the%20Wnt%20signaling%20pathway%20and%20impact%20prognosis.%20This%20study%20examines%20whether%20the%20different%20CTNNB1%20mutants%20%28T41A%2C%20S45F%29%20occurring%20in%20DTF%20tumors%20differentially%20affect%20Wnt%20signaling%20activity%2C%20which%20might%20explain%20the%20different%20disease%20course%20between%20DTF%20patients%20harboring%20different%20CTNNB1%20mutations.%5CnMATERIALS%20AND%20METHODS%3A%20Real-time%20polymerase%20chain%20reaction%20%28RT-PCR%29%20on%2061%20formalin%20fixed%20paraffin%20embedded%20DTF%20samples%20with%20known%20CTNNB1%20status%20was%20used%20to%20measure%20the%20relative%20mRNA%20expression%20level%20of%20Wnt%20target%20genes%20AXIN2%2C%20DKK1%20and%20CCND1.%20Additionally%2C%20publicly%20available%20mRNA%20expression%20data%20retrieved%20from%20the%20Gene%20Expression%20Omnibus%20of%20128%20DTF%20samples%20were%20used%20for%20an%20unsupervised%20cluster%20analyses%20based%20on%20the%20expression%20of%20a%20selection%20of%20Wnt%20targets.%5CnRESULTS%3A%20No%20statistically%20significant%20difference%20in%20relative%20expression%20levels%20of%20Wnt%20target%20genes%20AXIN2%2C%20DKK1%20and%20CCND1%20was%20identified%20between%20either%20CTNNB1%20wild-type%2C%20S45F%20or%20T41A%20mutated%20DTF%20samples.%20Moreover%2C%20the%20hierarchical%20cluster%20analyses%20using%20selected%20Wnt%20targets%20did%20not%20discriminate%20between%20different%20CTNNB1%20mutation%20types.%5CnCONCLUSIONS%3A%20No%20differences%20in%20the%20expression%20levels%20of%20Wnt%20target%20genes%20were%20observed%20between%20the%20different%20CTNNB1%20mutation%20types%20in%20DTF%20tumors.%20Further%20studies%20are%20needed%20to%20decipher%20the%20mechanism%20accounting%20for%20the%20diverse%20disease%20courses%20between%20DTF%20patients%20with%20different%20CTNNB1%20variants.%22%2C%22date%22%3A%2204%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejso.2018.09.019%22%2C%22ISSN%22%3A%221532-2157%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A22%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22DFUPS6V7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Croce%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCroce%2C%20Sabrina%2C%20Tom%20Lesluyes%2C%20Lucile%20Delespaul%2C%20Benjamin%20Bonhomme%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Val%26%23xE9%3Brie%20Velasco%2C%20Laetitia%20Mayeur%2C%20et%20al.%20%26%23x201C%3BGREB1-CTNNB1%20Fusion%20Transcript%20Detected%20by%20RNA-Sequencing%20in%20a%20Uterine%20Tumor%20Resembling%20Ovarian%20Sex%20Cord%20Tumor%20%28UTROSCT%29%3A%20A%20Novel%20CTNNB1%20Rearrangement.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGenes%2C%20Chromosomes%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2058%2C%20no.%203%20%282019%29%3A%20155%26%23x2013%3B63.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22694%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22694%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22GREB1-CTNNB1%20fusion%20transcript%20detected%20by%20RNA-sequencing%20in%20a%20uterine%20tumor%20resembling%20ovarian%20sex%20cord%20tumor%20%28UTROSCT%29%3A%20A%20novel%20CTNNB1%20rearrangement%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Croce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Bonhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Velasco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Mayeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flora%22%2C%22lastName%22%3A%22Rebier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Houda%22%2C%22lastName%22%3A%22Ben%20Rejeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20Glenn%22%2C%22lastName%22%3A%22McCluggage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Floquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Chakiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mojgan%22%2C%22lastName%22%3A%22Devouassoux-Shisheboran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Arnould%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerlinde%22%2C%22lastName%22%3A%22Averous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Mutations%20of%20CTNNB1%20have%20been%20implicated%20in%20tumorigenesis%20in%20many%20organs.%20However%2C%20tumors%20harboring%20a%20CTNNB1%20translocation%20are%20extremely%20rare%20and%20this%20translocation%20has%20never%20been%20reported%20in%20a%20uterine%20mesenchymal%20neoplasm.%20We%20report%20a%20novel%20translocation%20t%282%3B3%29%28p25%3Bp22%29%20involving%20the%20GREB1%20%28intron%208%29%20and%20CTNNB1%20%28exon%203%29%20in%20a%20uterine%20tumor%20resembling%20ovarian%20sex%20cord%20tumor%20%28UTROSCT%29%2C%20which%20exhibited%20extrauterine%20metastasis.%20The%20translocation%20detected%20by%20RNA-sequencing%20was%20validated%20by%20RT-PCR%2C%20and%20resulted%20in%20nuclear%20expression%20of%20%5Cu03b2-catenin.%20Juxtapositioning%20with%20GREB1%2C%20which%20is%20overexpressed%20in%20response%20to%20estrogens%2C%20resulted%20in%20overexpression%20of%20a%20truncated%20and%20hypophosphorylated%20nuclear%20%5Cu03b2-catenin%20in%20the%20primary%20and%20recurrent%20tumors.%20This%20accumulation%20of%20nuclear%20%5Cu03b2-catenin%20results%20in%20a%20constitutive%20activation%20of%20the%20Wnt%5C%2F%5Cu03b2-catenin%20signaling%20pathway%20with%20a%20major%20oncogenic%20effect.%20The%20CTNNB1%20gene%20fusion%2C%20promoted%20by%20an%20estrogen-responsive%20gene%20%28GREB1%29%2C%20could%20be%20a%20potential%20driver%20of%20tumorigenesis%20in%20this%20case%20and%20a%20therapeutic%20target%20with%20adapted%20inhibitors.%20RT-PCR%20and%20immunohistochemistry%20performed%20on%2011%20additional%20UTROSCTs%20showed%20no%20CTNNB1%20fusion%20transcript%20or%20nuclear%20%5Cu03b2-catenin%20immunoreactivity.%22%2C%22date%22%3A%2203%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fgcc.22694%22%2C%22ISSN%22%3A%221098-2264%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A36%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22USE3GCXY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chibon%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChibon%2C%20Frederic%2C%20Tom%20Lesluyes%2C%20Thibaud%20Valentin%2C%20and%20Sophie%20Le%20Guellec.%20%26%23x201C%3BCINSARC%20Signature%20as%20a%20Prognostic%20Marker%20for%20Clinical%20Outcome%20in%20Sarcomas%20and%20Beyond.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGenes%2C%20Chromosomes%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2058%2C%20no.%202%20%282019%29%3A%20124%26%23x2013%3B29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22703%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22703%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CINSARC%20signature%20as%20a%20prognostic%20marker%20for%20clinical%20outcome%20in%20sarcomas%20and%20beyond%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%5D%2C%22abstractNote%22%3A%22Prognostication%20is%20a%20key%20issue%20for%20sarcoma%20patients%26%23039%3B%20care%20as%20it%20triggers%20the%20therapeutic%20approach%20including%20chemotherapy%2C%20which%20is%20still%20not%20standard%20for%20localized%20patients.%20Current%20prognostic%20evaluation%2C%20based%20on%20the%20FNCLCC%20grading%20system%2C%20has%20recently%20been%20improved%20by%20the%20CINSARC%20signature%20outperforming%20histology-based%20grading%20system%20by%20identifying%20high-risk%20patients%20in%20every%20grade%2C%20even%20in%20those%20considered%20as%20low.%20CINSARC%20is%20an%20expression-based%20signature%20related%20to%20mitosis%20and%20chromosome%20integrity%20with%20prognostic%20value%20in%20a%20wide%20range%20of%20cancers%20additional%20to%20sarcoma.%20First%20developed%20with%20frozen%20material%2C%20CINSARC%20is%20now%20coupled%20with%20NanoString%20technology%20allowing%20evaluation%20from%20FFPE%20blocks%20used%20in%20clinical%20practice.%20Consequently%2C%20CINSARC%20is%20currently%20evaluated%20in%20clinical%20trials%20with%20a%20dual%20objective%20of%20demonstrating%20the%20benefit%20of%20chemotherapy%20in%20sarcoma%20patients%20and%20testing%20its%20response%20prediction.%20Considering%20its%20overarching%20value%20in%20oncology%2C%20its%20development%20is%20welcome%20in%20any%20cancers%20where%20the%20prognostication%20needs%20to%20be%20improved.%22%2C%22date%22%3A%2202%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fgcc.22703%22%2C%22ISSN%22%3A%221098-2264%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A24%3A23Z%22%7D%7D%5D%7D
Delespaul, Lucile, Candice Merle, Tom Lesluyes, Pauline Lagarde, Sophie Le Guellec, Gaëlle Pérot, Jessica Baud, et al. “Fusion-Mediated Chromosomal Instability Promotes Aneuploidy Patterns That Resemble Human Tumors.” Oncogene, July 3, 2019. https://doi.org/10.1038/s41388-019-0859-6.
Mauduit, Olivier, Vanessa Delcroix, Tom Lesluyes, Gaëlle Pérot, Pauline Lagarde, Lydia Lartigue, Jean-Yves Blay, and Frédéric Chibon. “Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas.” Cancers 11, no. 7 (July 1, 2019). https://doi.org/10.3390/cancers11070922.
Lesluyes, Tom, Jessica Baud, Gaëlle Pérot, Céline Charon-Barra, Axel You, Isabelle Valo, Céline Bazille, et al. “Genomic and Transcriptomic Comparison of Post-Radiation versus Sporadic Sarcomas.” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, June 26, 2019. https://doi.org/10.1038/s41379-019-0300-2.
Chibon, Frédéric, Elodie Darbo, and Gaëlle Pérot. “Leiomyosarcomas: Whole Genome Sequencing for a Whole Biology Characterization.” Current Opinion in Oncology, April 24, 2019. https://doi.org/10.1097/CCO.0000000000000550.
Le Loarer, François, Sophie Laffont, Tom Lesluyes, Franck Tirode, Cristina Antonescu, Anne-Catherine Baglin, Lucile Delespaul, et al. “Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum.” The American Journal of Surgical Pathology, March 1, 2019. https://doi.org/10.1097/PAS.0000000000001238.
Vitiello, Gerardo A., Timothy G. Bowler, Mengyuan Liu, Benjamin D. Medina, Jennifer Q. Zhang, Nesteene J. Param, Jennifer K. Loo, et al. “Differential Immune Profiles Distinguish the Mutational Subtypes of Gastrointestinal Stromal Tumor.” The Journal of Clinical Investigation, February 14, 2019. https://doi.org/10.1172/JCI124108.
Mauduit, Olivier, Céline Brulard, Tom Lesluyes, Vanessa Delcroix, Gaëlle Pérot, Nina Choublier, Mickael Michaud, et al. “RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas.” Cancers 11, no. 1 (January 11, 2019). https://doi.org/10.3390/cancers11010081.
Valentin, T., T. Lesluyes, S. Le Guellec, and F. Chibon. “Chemotherapy in Localized Soft Tissue Sarcoma: Will We Soon Have to Treat Grade 1 Tumors? Update on CINSARC Performances.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 30, no. 1 (January 1, 2019): 153–55. https://doi.org/10.1093/annonc/mdy465.
Timbergen, Milea J. M., Matthijs L. Janssen, Cornelis Verhoef, Dirk J. Grünhagen, Frederic Chibon, Marcel Smid, Stefan Sleijfer, and Erik A. C. Wiemer. “Wnt Targets Genes Are Not Differentially Expressed in Desmoid Tumors Bearing Different Activating β-Catenin Mutations.” European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 45, no. 4 (2019): 691–98. https://doi.org/10.1016/j.ejso.2018.09.019.
Croce, Sabrina, Tom Lesluyes, Lucile Delespaul, Benjamin Bonhomme, Gaëlle Pérot, Valérie Velasco, Laetitia Mayeur, et al. “GREB1-CTNNB1 Fusion Transcript Detected by RNA-Sequencing in a Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A Novel CTNNB1 Rearrangement.” Genes, Chromosomes & Cancer 58, no. 3 (2019): 155–63. https://doi.org/10.1002/gcc.22694.
Chibon, Frederic, Tom Lesluyes, Thibaud Valentin, and Sophie Le Guellec. “CINSARC Signature as a Prognostic Marker for Clinical Outcome in Sarcomas and Beyond.” Genes, Chromosomes & Cancer 58, no. 2 (2019): 124–29. https://doi.org/10.1002/gcc.22703.
LES MEMBRES DE L’ÉQUIPE
LES PARTENAIRES & FINANCIERS
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
Toulouse – FR
CRCT-Oncopole Suivre 1,434 1,195
Compte officiel du Centre de Recherches en Cancérologie de Toulouse
Prize for the best communication at the French Association for Pancreatic Cancer Research (AFRCP) day for @BousquetVaysse team at @crctoncopole
➡️
Nous contacter
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?
